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Abstract
The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientiﬁc opinion
re-evaluating the safety of calcium silicate (E 552), magnesium silicate (E 553a) and talc (E 553b) when
used as food additives. In 1991, the Scientiﬁc Committee on Food (SCF) established a group acceptable daily
intake (ADI) ‘not speciﬁed’ for silicon dioxide and silicates. The EFSA Panel on Food Additives and Nutrient
Sources added to Food (ANS) recently provided a scientiﬁc opinion re-evaluating the safety of silicon dioxide
(E 551) when used as a food additive. The Panel noted that the absorption of silicates and talc was very low;
there was no indication for genotoxicity or developmental toxicity for calcium and magnesium silicate and
talc; and no conﬁrmed cases of kidney effects have been found in the EudraVigilance database despite the
wide and long-term use of high doses of magnesium trisilicate up to 4 g/person per day over decades.
However, the Panel considered that accumulation of silicon from calcium silicate in the kidney and liver was
reported in rats, and reliable data on subchronic and chronic toxicity, carcinogenicity and reproductive
toxicity of silicates and talc were lacking. Therefore, the Panel concluded that the safety of calcium silicate
(E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b) when used as
food additives cannot be assessed. The Panel considered that there is no mechanistic rationale for a group
ADI for silicates and silicon dioxide and the group ADI established by the SCF is obsolete. Based on the food
supplement scenario considered as the most representative for risk characterisation, exposure to silicates
(E 552–553) for all population groups was below the maximum daily dose of magnesium trisilicate used as
an antacid (4 g/person per day). The Panel noted that there were a number of approaches, which could
decrease the uncertainties in the current toxicological database. These approaches include – but are not
limited to – toxicological studies as recommended for a Tier 1 approach as described in the EFSA Guidance
for the submission of food additives and conducted with an adequately characterised material. Some
recommendations for the revision of the EU speciﬁcations were proposed by the Panel.
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Summary
Calcium silicate (E 552), magnesium silicate (E 553a) and talc (E 553b) are authorised as food
additives according to Regulation (EC) No 1333/2008 on food additives and speciﬁcations have been
deﬁned in the Commission Regulation (EU) No 231/20121 for calcium silicate (E 552), magnesium
silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b).
In 1991, the Scientiﬁc Committee on Food (SCF) established a group acceptable daily intake (ADI) ‘not
speciﬁed’ for sodium silicate, silicon dioxide, calcium silicate, magnesium silicate and potassium silicate.
Although calcium silicate (E 552) and magnesium silicate (E 553(i)) may be described in terms of
theoretical oxides, the Panel concluded that they are not mixtures of silicon dioxide and calcium or
magnesium oxides; therefore, their deﬁnitions in the European Union (EU) speciﬁcations should be
revised accordingly.
Information on particle size of calcium silicate analysed by laser diffraction (LD) and transmission
electron microscopy (TEM) were provided. The Panel noted that these methods measure different particle
characteristics, which are reﬂected in the different numerical size-values obtained. Taking into account the
analysis by TEM provided by industry, calcium silicate falls under the deﬁnition of a nanomaterial
according to the Commission Recommendation 2011/696/EU. However, the Panel considered that the
dispersion method (sonication) of the sample before its analysis by TEM is not representative of the
common use of calcium silicate as a food additive. Following an European Food Safety Authority (EFSA)
request, no TEM data were provided for magnesium silicate (E 553a(i)) and magnesium trisilicate (E 553a
(ii)). Scanning electron microscope (SEM) data for talc indicated a particle size distribution of 20–40 lm.
The Panel considered that crystalline silica, ﬂuoride, aluminium and nickel may be present in
associated minerals in talc (E 553b) and, then, they could be present also in the food additive E 553b.
Therefore, maximum limits for them should be established in the EU speciﬁcations for talc (E 553b).
The Panel considered that silicate anion from both calcium silicate or magnesium trisilicate was
absorbed to a limited extent in rats. No data were available for magnesium silicate.
Based on a 2-year study with calcium silicate in rats, the Panel considered that at high doses (up to
5,000 mg/kg body weight (bw) per day), there was evidence of silicon accumulation in the liver and
kidney. The Panel considered that limited data in humans indicated that the silicate anion from
magnesium trisilicate is absorbed to a limited extent, then excreted in the urine (as determined from
urinary silicon measurements). No human data were available for calcium silicate or magnesium
silicate; however, the Panel considered that a read-across approach was appropriate and considered
that silicate anion from both calcium silicate or magnesium silicate would behave similarly.
The Panel noted that studies with synthetically produced talc in mice, rat and guinea pigs as well as
talc (baby powder) in hamsters indicated that less than 2% talc was systemically available, with low
levels seldom found in the liver.
The Panel considered that calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium
trisilicate (E 553a(ii)) and talc (E 553b) dissociate to a limited extent in the gastrointestinal tract into
silicates and their corresponding cations. The resulting low amounts of calcium and magnesium ions
were considered not to disturb normal physiological processes and therefore, are not discussed further
in this opinion.
The Panel considered that calcium silicate, magnesium silicate and talc have a low acute oral
toxicity. No studies were available for magnesium trisilicate.
No adverse effects were observed in short-term toxicity studies in rats with calcium silicate,
magnesium trisilicate or talc. The kidney effects observed in dogs were most probably related to the
large amount of test compound consumed as a bolus dose by the animals. The effects on the kidney
reported in guinea pigs could be due to higher concentrations of silicate in the primary urine as a
consequence of lower glomerular ﬁltration rates in guinea pigs (2.29 mL plasma/min per kg) as
compared to rats (4.63 mL plasma/min per kg). The Panel noted that in humans the glomerular
ﬁltration rate (3.56 mL plasma/min per kg) is higher than in guinea pigs and, furthermore, kidney
effects have not been found in humans in the EudraVigilance database despite the wide and long-term
use of high doses of magnesium trisilicate (up to 4 g/person per day) as an antacid over decades.
The Panel considered that the available data did not raise concern with respect to genotoxicity of
calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc
(E 553b) when used as food additives.
Re-evaluation of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
(E 553a(ii)) and talc (E 553b)
1 Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down speciﬁcations for food additives listed in Annexes II
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In a 2-year study in rats, not performed according to current standards, calcium silicate had no
effect on mortality at a dose up to 5,000 mg/kg bw per day. No gross pathology or histopathological
ﬁndings that could be attributed to calcium silicate were observed in the 500 and 2,500 mg/kg bw per
day groups. However, in the absence of clinical chemistry data, given the respiratory infection of
animals and only 15 animals/sex per group, the Panel considered that this study was too limited to
conclude on the chronic toxicity of calcium silicate. However, the Panel noted that no carcinogenic
effects were reported in this study. There were no data for oral chronic toxicity/carcinogenicity of talc.
No reproductive toxicity studies were available. Prenatal developmental toxicity studies with calcium
silicate by gavage during organogenesis in mice, rats and hamsters, and with talc in mice and rats, up
to 1,600 mg/kg bw per day (the highest dose tested), showed no dose-related developmental effects.
The Panel noted that cases of renal calculi were rarely reported considering the high number of
exposed humans to magnesium trisilicate used as an antacid. The Panel applied the WHO algorithm
for assessing the association between adverse events and drug intake, and found that the association
between silicate antacid use and renal calculi was ‘possible’ but not ‘deﬁnite’, which does not exclude
that the occurrence of renal calculi and intake of silicates would be a chance ﬁnding.
In the available data on subacute toxicity, genotoxicity and developmental toxicity studies, no
adverse effects were reported for silicates and talc. From the only chronic toxicity study (with calcium
silicate) available, there was no indication for carcinogenicity. However, due to the limitations of this
study, it was not possible to draw a reliable conclusion on the chronic toxicity and carcinogenicity of
calcium silicate. Furthermore, no subchronic and reproductive toxicity studies with silicates or talc were
available.
The Panel noted that in 1991, the SCF established a group ADI ‘not speciﬁed’ for sodium silicate,
silicon dioxide, calcium silicate, magnesium silicate and potassium silicate presumably on the basis that
they share a common moiety. The Panel noted that more recent evidence suggested that this
assumption might not be valid. Therefore, the Panel considered that on the evidence currently available,
there is no mechanistic rationale for a group ADI for silicates and silicon dioxide. Therefore the
Panel considered this group ADI obsolete.
Due to the limitations in the available toxicological database for individual silicates, the Panel was
unable to derive ADIs for calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
(E 553a(ii)) and talc (E 553b).
Silicates (E 552–553) are authorised in 28 food categories, including FC 0, according to Annex II to
Regulation (EC) No 1333/2008. Their use in FC 0 means that they are ‘permitted in all categories of
foods excluding foods for infants and young children, except where speciﬁcally provided for’. Silicates
(E 552–553) are also authorised according to Annex III to Regulation (EC) No 1333/2008 (Parts 1, 2
and 5 A) in food-improving agents and nutrients, except nutrients intended for foods for infants and
young children. As such, silicates (E 552–553) can be found in many foods via carry-over. The industry
provided use levels for silicates (E 552–553) for their use according to Annex II. No analytical data on
the concentration of these food additives in foods were made available by the Member States.
Dietary exposure to silicates (E 552–553) from their use as food additives according to Annex II was
calculated for different exposure scenarios based on the provided use levels. 98% of the reported use
levels referred to the use of talc (E 553b). This was in line with the information from the Mintel’s Global
New Products Database (GNPD), showing that 89% of the foods labelled with silicates (E 552–553) were
labelled to contain talc (E 553b). Therefore, the Panel noted that the calculated exposure reﬂects chieﬂy
the exposure to talc (E 553b).
Additionally, 91% of the reported use levels were related to the use of silicates in food
supplements. The Panel noted that the main food category labelled with silicates (E 552–553) in the
Mintel GNPD was also food supplements (Appendix B). Therefore, the Panel considered the food
supplements consumers only scenario as the most appropriate scenario for risk characterisation of
silicates (E 552–553). Dietary exposure to silicates (E 552–553) via this exposure scenario was up to
31 mg/kg bw per day at the mean level in children and up to 46 mg/kg bw per day at the high (P95)
level in the elderly.
The exposure assessment was hampered by several uncertainties. Overall, it was considered that
the exposure was most likely overestimated due to the use levels used and assumptions made in the
exposure assessment. Furthermore, the Panel noted that no foods belonging to an important
contributing food category in all population groups, i.e. ripened cheese, were labelled to contain
silicates (E 552–553) according to the Mintel GNPD.
Re-evaluation of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
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The Panel noted that:
• the absorption of silicates and talc was very low;
• there was no indication for genotoxicity or developmental toxicity for calcium and magnesium
silicate and talc;
• no conﬁrmed cases of kidney effects have been found in the EudraVigilance database despite
the wide and long-term use of high doses of magnesium trisilicate up to 4 g/person per day
over decades.
However, the Panel considered that accumulation of silicon from calcium silicate in the kidney and
liver was reported in rats, and reliable data on subchronic and chronic toxicity, carcinogenicity and
reproductive toxicity of silicates and talc were lacking. Therefore, the Panel concluded that the safety
of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc
(E 553b) when used as food additives cannot be assessed.
Based on the food supplement scenario considered as most representative for risk characterisation,
exposure to silicates (E 552–553) for all population groups was below the maximum daily dose of
magnesium trisilicate used as an antacid (4 g/person per day).
The Panel noted that there were a number of approaches which could decrease the uncertainties in
the current toxicological database. These approaches include – but are not limited to – toxicological
studies as recommended for Tier 1 approach as described in the EFSA Guidance for the submission of
food additives (EFSA ANS Panel, 2012) and conducted with an adequately characterised material.
Since the available data showed that nano particles are present in calcium silicate (E 552), the studies
should be conducted with a material that contains a fraction of nanoparticles typical for silicates used
as food additives.
The Panel recommended that:
• the European Commission considers the revision of the EU speciﬁcations for calcium silicate
(E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b) in
order to include better deﬁnitions, assays in line with the deﬁnitions, and characterisation of
particle size distributions (using appropriate statistical descriptors (e.g. range, median,
quartiles) as well as the percentages (in number and by mass) of particles in the nanoscale
(with at least one dimension < 100 nm). With regard to the characterisation of the particle
size distribution, the analytical methodologies applied should comply with those recommended
in the EFSA Guidance on risk assessment of the application of nanoscience and
nanotechnologies in the food and feed chain (EFSA Scientiﬁc Committee, 2018)).
• in ﬁrst instance, toxicological studies as recommended for a Tier 1 approach as described in
the EFSA Guidance for the submission of food additives (EFSA ANS Panel, 2012) should be
conducted with adequately characterised material(s) in order to decrease the uncertainties in
the current toxicological database.
• more data on the actual usage and use levels of silicates (E 552, E 553a(i)), E 553a(ii)) should
be provided because most of the data submitted were for talc (E 553b).
• the European Commission considers lowering the current limits for toxic elements (arsenic,
lead and mercury) in the EU speciﬁcations for calcium silicate (E 552), magnesium silicate
(E 553a(i)), magnesium trisilicate, (E 553a(ii)) and talc (E 553b) in order to ensure that the
food additives will not be a signiﬁcant source of exposure to these toxic elements in food.
• the European Commission considers inclusion of maximum limits for aluminium, nickel, ﬂuoride
and crystalline silica (alpha-quartz) in the EU speciﬁcations for talc (E 553b).
Re-evaluation of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
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1. Introduction
The present opinion document deals with the re-evaluation of calcium silicate (E 552), magnesium
silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b) when used as food additives.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
Regulation (EC) No 1333/20082 of the European Parliament and of the Council on food additives
requires that food additives are subject to a safety evaluation by the European Food Safety Authority
(EFSA) before they are permitted for use in the European Union. In addition, it is foreseen that food
additives must be kept under continuous observation and must be re-evaluated by the European Food
Safety Authority (EFSA).
For this purpose, a programme for the re-evaluation of food additives that were already
permitted in the European Union before 20 January 2009 has been set up under the Regulation
(EU) No 257/20103. This Regulation also foresees that food additives are re-evaluated whenever
necessary in the light of changing conditions of use and new scientiﬁc information. For efﬁciency
and practical purposes, the re-evaluation should, as far as possible, be conducted by group of food
additives according to the main functional class to which they belong.
The order of priorities for the re-evaluation of the currently approved food additives should be set
on the basis of the following criteria: the time since the last evaluation of a food additive by the
Scientiﬁc Committee on Food (SCF) or by EFSA, the availability of new scientiﬁc evidence, the extent
of use of a food additive in food and the human exposure to the food additive taking also into account
the outcome of the Report from the Commission on Dietary Food Additive Intake in the EU4 of 2001.
The report ‘Food additives in Europe 20005’ submitted by the Nordic Council of Ministers to the
Commission, provides additional information for the prioritisation of additives for re-evaluation. As
colours were among the ﬁrst additives to be evaluated, these food additives should be re-evaluated
with a highest priority.
In 2003, the Commission already requested EFSA to start a systematic re-evaluation of authorised
food additives. However, as a result of adoption of Regulation (EU) 257/2010, the 2003 Terms of
References are replaced by those below.
1.1.2. Terms of Reference
The Commission asks EFSA to re-evaluate the safety of food additives already permitted in the
Union before 2009 and to issue scientiﬁc opinions on these additives, taking especially into account the
priorities, procedures and deadlines that are enshrined in the Regulation (EU) No 257/2010 of 25
March 2010 setting up a programme for the re-evaluation of approved food additives in accordance
with the Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food
additives.
1.2. Information on existing authorisations and evaluations
Calcium silicate (E 552), magnesium silicate (E 553a) and talc (E 553b) are authorised as food
additives according to Regulation (EC) No 1333/2008 on food additives and speciﬁcations have been
deﬁned in the Commission Regulation (EU) No 231/20121 for calcium silicate (E 552), magnesium
silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b).
In 1991, the SCF established a group acceptable daily intake (ADI) ‘not speciﬁed’ for sodium
silicate, silicon dioxide, calcium silicate, magnesium silicate and potassium silicate. The Committee
argued that the available data conﬁrmed the biological inertness of these compounds (SCF, 1991). The
Re-evaluation of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
(E 553a(ii)) and talc (E 553b)
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354, 31.12.2008, p. 16–33.
3 Commission Regulation (EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of approved food
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives.
OJ L 80, 26.3.2010, p. 19–27.
4 COM(2001) 542 ﬁnal.
5 Food Additives in Europe 2000, Status of safety assessments of food additives presently permitted in the EU, Nordic Council of
Ministers, TemaNord 2002, 560.
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SCF also concluded that: ‘any silicate absorbed is excreted by the kidney without evidence of toxic
accumulation in the body, except for the reported damage to dog kidney by magnesium trisilicate and
sodium silicate’.
Silicates have been discussed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA)
on several occasions (JECFA, 1969, 1974, 1986, 1987). JECFA conducted its ﬁrst toxicological
evaluation of amorphous silicon dioxide, and aluminium, calcium, magnesium and sodium
aluminosilicates (including talc and magnesium trisilicate) in 1969 (JECFA, 1969). In this evaluation, it
was concluded that ‘The available data on orally administered silica and silicates, including ﬂumed
silicate dioxide, appear to substantiate the biological inertness of these compounds.[. . .] This
information taken together with human clinical experience and the ubiquitous occurrence of these
compounds in the environment does not point to any signiﬁcant toxic effects when these substances
are used as food additives’. Therefore, the use of these substances as food additives was ‘not limited
except for good manufacturing practice’ (JECFA, 1969). In 1974, the toxicological monograph was
expanded to include new data (JECFA, 1974). This new evaluation concluded that the ADI for silicon
dioxide and certain silicates, except magnesium silicate and talc, to be ‘not limited’, whereas for
magnesium and talc concluded an ADI ‘temporarily not limited’. Further studies on magnesium
trisilicate elucidating the reported kidney damage in dogs, and long-term feeding studies on talc,
speciﬁed as free from asbestos-like particles were requested by JECFA in 1974 (JECFA, 1974). In 1976,
JECFA reiterated the need for a long-term study on talc (of an acceptable speciﬁcation) before an
acceptable daily intake (ADI) could be established. The committee requested short-term studies to
differentiate between medicinal magnesium trisilicate and the insoluble magnesium silicate in food
processing. Magnesium silicate was allocated an ‘ADI not speciﬁed’ (JECFA, 1976).
In 1980, JECFA extended the temporary ADI ‘not speciﬁed’ for talc and requested a long-term
study by 1983 (JECFA, 1980). However, the study was not available and talc was therefore removed
from the agenda in 1983. Owing to the revised speciﬁcations (satisfactory method for estimating
asbestos and does not contain magnesium trisilicate) for talc by JECFA in 1986, the request for a long-
term feeding study was withdrawn. An ADI ‘not speciﬁed’ was allocated for talc, provided that the talc
used in food processing complied with the new speciﬁcations (JECFA, 1987).
The temporary ADI ‘not speciﬁed’ for magnesium silicate was extended to 1982 because the
previously requested dog studies were not available (JECFA, 1980). In 1982, the requested studies
were still not available, however the existing tentative speciﬁcations were revised excluding
magnesium trisilicate and concluded that the ADI status should be reallocated as ‘not speciﬁed’
(JECFA, 1982). This ADI was conﬁrmed in 1986 (JECFA, 1986).
The Nordic Council of Ministers (TemaNord) summarised the ﬁndings of JECFA and the SCF and
concluded that ‘an immediate re-evaluation is not needed but the next evaluation should include a
proper carcinogenicity test’ (TemaNord, 2002).
The ANS Panel evaluated calcium silicate and silicon dioxide/silicic acid gel added for nutritional
purposes to food supplements and concluded that the proposed use and use levels of calcium silicate
in food supplements (these vary depending on the formulation, but is normally the quantity necessary
to supply not more than 100 mg silicon/day and up to 140 mg calcium/day) is of no safety concern,
provided that it complies with the speciﬁcations set for its use as a food additive (EFSA ANS Panel,
2009).
The UK Expert Group on Vitamins and Minerals (2003) reviewed data relating to silicon and,
although oral toxicity data were sparse, derived a ‘Safe Upper Limit’ of 25 mg silicon/kg body weight
(bw) per day based on a carcinogenicity study that tested silicon dioxide (Takizawa et al., 1988).
The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provided a scientiﬁc
opinion re-evaluating the safety of silicon dioxide (E 551) when used as a food additive (EFSA ANS
Panel, 2018), not covering the silicates (E 552–553).
IARC monographs on silicates and talc were prepared in 1987, 1997 and 2010 (IARC, 1987, 1997,
2010). However, most of the data in these monographs relate to the inhalation toxicity and do not
include any good quality oral chronic toxicity or carcinogenicity studies. Hence, the IARC monographs
did not make a conclusion on the carcinogenic potential of silicates following oral ingestion.
The Cosmetic Ingredient Review Expert Panel has assessed the safety of talc for use in cosmetics
and concluded that talc is safe for use in cosmetics using current practices of use and concentration.
However, it was recommended that talc should not be applied to the skin when the epidermal barrier
is missing or signiﬁcantly disrupted (CIR, 2013; Fiume et al., 2015).
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Calcium silicate, magnesium silicate, magnesium trisilicate and talc are permitted as ingredients in
cosmetic products (European Commission database-CosIng6). Calcium silicate is included in the
European Union Register7 of feed additives (Regulation (EC) No 1831/20038).
Calcium silicate (silicic acid, calcium salt; EC Number 215-710-8), magnesium silicate (silicic acid,
magnesium salt; EC Number 215-681-1), magnesium trisilicate (dimagnesium trisilicon octaoxide,
EC Number 329-076-7) and talc have been registered under the REACH Regulation 1907/20069
(ECHA, online).
2. Data and methodologies
2.1. Data
The ANS Panel was not provided with a newly submitted dossier. EFSA launched public calls for
data10,11 to collect information from interested parties.
The Panel based its assessment on information submitted to EFSA following the public calls for
data, information from previous evaluations and additional available literature up to May 2018.
Attempts were made at retrieving relevant original study reports on which previous evaluations or
reviews were based however these were not always available to the Panel.
Food consumption data used to estimate the dietary exposure to silicates (E 552–553) were derived
from the EFSA Comprehensive European Food Consumption Database (Comprehensive Database12).
The Mintel’s Global New Products Database (GNPD) was used to verify the use of calcium silicate
(E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b) in food
products. The Mintel’s GNPD is an online database that contains the compulsory ingredient information
present on the label of numerous food products.
2.2. Methodologies
This opinion was formulated following the principles described in the EFSA Guidance on
transparency with regard to scientiﬁc aspects of risk assessment (EFSA Scientiﬁc Committee, 2009)
and following the relevant existing guidance documents from the EFSA Scientiﬁc Committee.
The ANS Panel assessed the safety of silicates (E 552–553) as food additives in line with the
principles laid down in Regulation (EU) 257/2010 and in the relevant guidance documents: Guidance
on submission for food additive evaluations by the SCF (2001) and taking into consideration the
Guidance for submission for food additive evaluations in 2012 (EFSA ANS Panel, 2012).
When the test substance was administered in the feed or in the drinking water, but doses were not
explicitly reported by the authors as mg/kg bw per day based on actual feed or water consumption,
the daily intake was calculated by the Panel using the relevant default values as indicated in the EFSA
Scientiﬁc Committee Guidance document (EFSA Scientiﬁc Committee, 2012) for studies in rodents or,
in the case of other animal species, by JECFA (2000). In these cases, the daily intake was expressed
as equivalent. When in human studies in adults (aged above 18 years), the dose of the test substance
administered was reported in mg/person per day, the dose in mg/kg bw per day was calculated by the
Panel using a body weight of 70 kg as default for the adult population as described in the EFSA
Scientiﬁc Committee Guidance document (EFSA Scientiﬁc Committee, 2012).
Dietary exposure to silicates (E 552–553) from their use as food additives was estimated by
combining the food consumption data available within the EFSA Comprehensive Database with the
maximum permitted levels according to Annex II to Regulation (EC) No 1333/2008 and reported use
levels submitted to EFSA following a call for data. The exposure was estimated according to different
scenarios (see Section 3.4.1). Uncertainties in the exposure assessment were identiﬁed and discussed.
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8 Regulation (EC) No 1831/2003 of the European Parliament and the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, 29–43.
9 Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the
Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). OJ L 396, 30.12.2006.
10 Call for scientiﬁc data on miscellaneous food additives permitted in the EU and belonging to several functional classes.
Published: 15 February 2012. Available online: https://www.efsa.europa.eu/sites/default/files/consultation/120215.pdf
11 Call for food additives usage level and/or concentration data in food and beverages intended for human consumption
(Batch 5). Published 24 May 2016. Available online: https://www.efsa.europa.eu/en/data/call/160524
12 Available online: http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
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3. Assessment
3.1. Technical data
3.1.1. Identity of the substances
Calcium silicate (E 552)
According to Commission Regulation (EU) No 231/2012, the food additive calcium silicate (E 552) is
deﬁned as ‘a hydrous or anhydrous silicate with varying proportions of CaO and SiO2. The product
should be free of asbestos’. No molecular formula or molecular weight is indicated. The EINECS/EC
Number is 215-710-8 and its chemical name is calcium silicate.
Calcium silicate (E 552) is described in Commission Regulation (EU) No 231/2012 as a white to off-
white free-ﬂowing powder that remains so after absorbing relatively large amounts of water or other
liquids.
According to industry (CEFIC, 2017a (Documentation provided to EFSA n. 4)), calcium silicate
(E 552) is the silicic acid salt of calcium with CAS 1344-95-2 and EINECS No 215-710-8. While it can
be described in terms of hypothetical oxides, it is not a mixture of silicon dioxide and calcium oxide.
The Panel noted that X-ray diffraction data (CEFIC, 2017a (Documentation provided to EFSA n. 4))
conﬁrmed that calcium silicate is not a mixture of silicon dioxide and calcium oxide.
According to the EC inventory (online),13 the molecular formula for EC No 215-710-8 is CaO3Si and
the structural formula is shown in Figure 1.
Solubility: It is insoluble in water and in ethanol (JECFA, 2015) by following the solubility test
described in Volume 4 (JECFA), which foresees a waiting time of 5 min.
In the REACH registration dossier, water solubility of calcium silicate has been reported to be in the
region of 260 mg/L, using EU Method A.6 (which extends the measurement time for several days)
(CEFIC, 2017a (Documentation provided to EFSA n. 4)).
According to industry (CEFIC, 2017a (Documentation provided to EFSA n. 4)), the time needed to
achieve solubility equilibrium at room temperature is between 3 and 6 days based on studies made
with synthetic amorphous silicon dioxide. The solubility of three commercial calcium silicates measured
according to this approach varies between 220 and 330 mg/L, depending on the manufacturing
parameters and calcium content (OECD 1054 method). However, the Panel noted that a solubility of
220–330 mg/L, equal to one part of substance dissolved in 4,545-3,030 parts of water, even when the
equilibrium is reached, would classify the substance as ‘very slightly soluble’ according to the
classiﬁcation of the solubility by JECFA (2016).
Synonyms: silicic acid calcium salt (CEFIC, 2017a (Documentation provided to EFSA n. 4)).
Information on particle size
Industry (CEFIC, 2017a (Documentation provided to EFSA n. 4)) provided information on the
particle size distribution of three types of commercial products of E 552 obtained from two different
producers. Laser diffraction (LD) (ultrasonication in water for 1 or 2 min) was used as the method of
measurement. The overall particle size distribution ranges (by volume) were: d50 (median) between
7.99 and 14.48 lm; d10 between 2.30 and 5.80 lm; d90 between 16.83 and 35.49 lm. No particles
had sizes below 100 nm.
Using transmission electron microscopy (TEM), after dispersion the sample in a water–isopropanol
mixture and ultrasonication for 3 min, the values (by number) were as follows: 24 nm for 1 type of
commercial material and 12 nm for the second one (CEFIC, 2017a (Documentation provided to EFSA
n. 4)). Using this method, 100% of particles had sizes below 100 nm, therefore, these two materials fall
under the deﬁnition of nanomaterial according to the Commission Recommendation 2011/696/EU14.
Figure 1: Structural formula for calcium silicate (EC inventory, online)13
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Magnesium silicate (E 553a(i))
According to Commission Regulation (EU) No 231/2012, the food additive magnesium silicate
(E 553a(i)) is deﬁned as ‘a synthetic compound of which the molar ratio of magnesium oxide to silicon
dioxide is approximately 2:5’. No chemical formula, molecular weight and EINECS number indicated.
Physical description: It is a very ﬁne, white, odourless powder, free from grittiness (Commission
Regulation (EU) No 231/2012).
According to industry (CEFIC, 2017b (Documentation provided to EFSA n. 5)), magnesium silicate
(E 553(i)) – CAS 1343-88-0 and an EINECS number 215-681-1 – has the name ‘Synthetic amorphous
magnesium silicate, with molar ratio (SiO2:MgO) range of 1.4-4’. While it can be described in terms of
hypothetical oxides, it is not a mixture of silicon dioxide and magnesium oxide. The Panel agreed with
this conclusion.
According to the EC inventory (online),13 the molecular formula for EC Number 215-681-1 is
MgO3Si and its structural formula is shown in Figure 2.
The Panel noted that, according to the deﬁnition given in the EU speciﬁcations, the food additive
E 553a(i) has a molar ratio of magnesium oxide to silicon dioxide of approximately 2:5. This
stoichiometry does not correspond with magnesium silicate (MgO3Si) as presented in the EC inventory.
13
According to industry, the time needed to achieve solubility equilibrium at room temperature is
between 3 and 6 days based on studies made with synthetic amorphous silicon dioxide (CEFIC, 2017b
(Documentation provided to EFSA n. 5)). The solubility of three non-food-grade commercial magne-
sium silicates by following this approach varied between 127 and 268 mg/L. However, the Panel noted
that a solubility of 127–268 mg/L, equal to one part of substance dissolved in 4,874-3,731 parts of
water, even when the equilibrium is reached, would classify the substance as ‘very slightly soluble’
according to the classiﬁcation of the solubility by JECFA (2016).
Synonyms: silicic acid magnesium salt (CEFIC, 2017b (Documentation provided to EFSA n. 5)).
Information on particle size
Industry (CEFIC, 2017; Documentation provided to EFSA n. X) provided information on the particle
size distributions of two types of commercial products of E 553a(i). LD in water (no ultrasonication) was
used as the method of measurement. The particle size distribution ranges (by volume), for the ﬁrst type
of E 553a(i) were: d50 (median) between 60 and 80 lm, d10 ≥ 10 lm, d90 ≥ 120 lm; and for the
second type: d50 (median) between 5 and 20 lm, d10 ≥ 2 lm, d90 ≥ 20 lm.
No data measured by TEM were provided following a request from EFSA.
Magnesium trisilicate (E 553a(ii))
According to Commission Regulation (EU) No 231/2012, the food additive magnesium trisilicate
(E 553a(ii)) is identiﬁed as:
Chemical name: magnesium trisilicate
EINECS Number: 239-076-7
Chemical formula: Mg2Si3O8 • nH2O
Description: ﬁne, white powder, free from grittiness.
The Panel noted that the EINECS Number reported in EU speciﬁcations corresponds to the CAS
Number 14987-04-3 (anhydrous form), while the chemical formula given in the EU speciﬁcations refers
to an hydrated form.
Solubility: It is insoluble in water and ethanol (Elmore, 2003)
Synonyms: dimagnesium trisilicon octaoxide (EC inventory, online)13
Structural formula is shown in Figure 3.
Figure 2: Structural formula for magnesium silicate (EC inventory, online)13
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Information on particle size
Industry (CEFIC, 2017; Documentation provided to EFSA n. X) provided information on the particle
size distributions of one type of commercial product of E 553a(ii). LD (80 s ultrasonication in a 0.1%
solution of tetrasodium pyrophosphate in water) was used as the method of measurement. The
particle size distribution ranges (by volume) were: d50 (median) between 10 and 20 lm, d10 ≥ 3 lm,
d90 ≥ 20 lm.
No data measured by TEM were provided following a request from EFSA.
Talc (E 553b)
According to Commission Regulation (EU) No 231/2012, the food additive talc (E 553b) is deﬁned as
‘naturally occurring form of hydrous magnesium silicate containing varying proportions of such associated
minerals as alpha-quartz, calcite, chlorite, dolomite, magnesite, and phlogopite’ and is identiﬁed as:
Chemical name: Magnesium hydrogen metasilicate
EINECS Number: 238-877-9
Chemical formula: Mg3(Si4O10)(OH)2
Molecular weight: 379.22 g/mol
Description: It is a light, homogeneous, white or almost white powder, and greasy to the touch.
The Panel noted that the chemical formula and molecular weight indicated in the EU speciﬁcations
refer to the pure mineral magnesium hydrogen metasilicate.
The EINECS Number indicated in the EU speciﬁcations for E 553b corresponds to CAS number
14807-96-6.
Solubility: It is insoluble in water and ethanol (Commission Regulation (EU) No 231/2012). It is
soluble in hot concentrated phosphoric acid (Fiume et al., 2015). According to Rashid et al. (2011), it is
practically insoluble in water and in ‘dilute’ mineral acids, but it dissolves practically at concentrations up
to 3 M of the acid and dissociates under these conditions to magnesium cations and silicic acid. The
Panel assumed that, when talc dissociates, the associated water molecules are liberated in the solution.
Synonyms: talcum
According to industry (EUROTALC, 2012 (Documentation provided to EFSA n. 10)), a commercial
brand of talc is a mixture of 75% (w/w) talc, 9% (w/w) chlorite (no further information on the variety
of chlorite), 9% (w/w) dolomite (CaMg(CO3)2)
15 and 7% (w/w) magnesite (MgCO3).
15
ahttps://pubchem.ncbi.nlm.nih.gov/compound/5311266#section=2D-Structure
Figure 3: Structural formula for anhydrous magnesium trisilicatea
Figure 4: Schematic structure of talc (© SAGE Publications, Fiume et al., 2015)
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Chlorite minerals have a general chemical composition of [(X,Y)4-6(Si,Al)4O10(OH,O)8. The ‘X’ and ‘Y’
in the formula represent ions, which might include: Fe2+, Fe3+, Mg2+, Mn2+, Ni2+, Zn2+, Al3+, Li1+ or
Ti4+].15 Among chlorites, there are minerals with speciﬁc composition, e.g. donbassite, Al13(Al3Si9O30)
(OH)24, or nimite (Ni,Mg,Al)6(Si,Al)4O10(OH)8.
15
The Panel noted that in the case of the possible presence of donbassite (the chlorite with highest
aluminium content), the aluminium content is 27.5%, and consequently, the aluminium content in the
food additive talc (E 553b) could be up to 2.47% when assuming that 9% of the food additive contain
chlorite (donbassite).
The Panel noted that in the case of the possible presence of nimite (the chlorite with highest nickel
content), the nickel content is 29.9% and consequently the nickel content in the food additive talc
(E 553b) could be up to is 2.7% in the hypothesis that 9% of the food additive contain chlorite
(nimite).
According to industry (EUROTALC, 2012 (Documentation provided to EFSA n. 10)), a commercial
brand of talc is a natural association of talc and chlorite at greater than or equal to 95% where
chlorite is deﬁned as (Mg.Fe)5 Al[AlSi3O10][OH]8 (CAS No 1318-59-8). In this chlorite, the aluminium
content is 6.5%. There is no information on the proportion of chlorite in the commercial talc.
According to industry, another commercial brand of talc contains at least 94% of talc [Mg3(Si4O10)
(OH)2].
According to EU speciﬁcations for talc (E 553b), phlogopites can also be present as associated
minerals. Some phlogopites with speciﬁc composition (e.g. ﬂuorophlogopite KMg3(AlSi3O10)F2) may
contain up to 9% of ﬂuorine.
16
The Panel noted that the various proportions chlorite or phlogopite, which can be present in talc,
largely inﬂuence the amounts of impurities such as nickel or aluminium, in the food additive.
Information on particle size
Industry (EUROTALC, 2012 (Documentation provided to EFSA n. 10)) provided information on
the particle size distribution of two lots of talc (E 553b). LD was used as measuring method of
suspensions dispersed in water. The particle size distributions ranges (by volume) were as follows:
d50, 13.94–14.32 lm; d10, 3.26–3.76 lm; d90, 36.79–39.64 lm.
Additional information on talc (E 553b) analysed with a scanning electron microscope (SEM)
indicated that the particles have an irregular shape and are non-porous and exist as two different
particle sizes of 40 and 20 lm. The speciﬁc surface area (MSSA) of the ﬁnest E 553b is between 5 and
7 m2/g (corresponding to VSSA of 14–19.6 m2/cm3, using talc density 2.8 g/cm3) (EUROTALC, 2018b;
(Documentation provided to EFSA n. 12)).
3.1.2. Speciﬁcations
The speciﬁcations for calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate,
(E 553a(ii)) and talc (E 553b) as deﬁned in the Commission Regulation (EU) No 231/2012 and by
JECFA (2015) are listed in Tables 1, 2, 3 and 4.
Table 1: Speciﬁcations for calcium silicate (E 552) according to Commission Regulation (EU) No
231/2012 and JECFA (2015)
Commission Regulation (EU)
No 231/2012
JECFA (2015)
Deﬁnition Calcium silicate is a hydrous or
anhydrous silicate with varying
proportions of CaO and SiO2. The
product should be free of asbestos
Calcium silicate is an inorganic substance that is a
hydrous or anhydrous substance with varying proportions
of calcium as calcium oxide, and silicon as silicon dioxide.
It is prepared by various reactions between siliceous
material (e.g. diatomaceous earth) and calcium
compounds (e.g. lime, calcium hydroxide)
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The Panel noted that in the JECFA speciﬁcations, a test for silicon is used as a surrogate for the
identiﬁcation of silicate in calcium silicate, whereas a test for silicate is required in the EU
speciﬁcations. The Panel also noted that there is no reference to solubility in EU speciﬁcations, where
there is one in JECFA speciﬁcations.
The Panel noted that, according to the assay proposed in the EU speciﬁcations, silicon dioxide (SiO2)
can be up to 95%; this means that calcium oxide would be 5% which represents 9.7% as calcium
silicate in the ﬁnal product. Additionally if the content calcium oxide is at the minimum permitted of 3%,
7.2% of calcium silicate would be in the ﬁnal product. The Panel noted that the limits in the assay
should be reviewed in order to clarify the purity of calcium silicate as such in the food additive.
Commission Regulation (EU)
No 231/2012
JECFA (2015)
Assay Content on the anhydrous basis:
• as SiO2 not less than 50%
and not more than 95%
• as CaO not less than 3% and
not more than 35%
Not less than 50% and not more than 95% of silicon
dioxide (SiO2) and not less than 3% and not more than
35% of calcium oxide (CaO), calculated on the ignited
basis
Description White to off-white free-ﬂowing powder that
remains so after absorbing relatively large
amounts of water or other liquids
Very ﬁne, white or off-white powder
with low bulk density and high physical
water absorption
Identiﬁcation Test for silicate
Passes test
Passes test [test for silicon]
Test for calcium
Passes test
Passes test
pH
–
8.4–12.5 (5% slurry)
Gel formation
Forms a gel with
mineral acids
–
Solubility
–
Insoluble in water and ethanol
Purity
Loss on drying Not more than 10% (105°C, 2 h) Not more than 10% (105°, 2 h)
Loss on ignition Not less than 5% and not more than 14%
(1,000°C, constant weight)
5.0–14.0% on the dried basis
(1,000°C, constant weight)
Sodium Not more than 3% –
Fluoride Not more than 50 mg/kg Not more than 50 mg/kg
Arsenic Not more than 3 mg/kg Not more than 3 mg/kg
Lead Not more than 2 mg/kg Not more than 5 mg/kg
Mercury Not more than 1 mg/kg –
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The Panel also noted that there is no reference to solubility in EU speciﬁcations, where there is one
in JECFA speciﬁcations.
Table 2: Speciﬁcations for magnesium silicate (E 553a(i)) according to Commission Regulation (EU)
No 231/2012 and JECFA (2011)
Commission Regulation
(EU) No 231/2012
JECFA (2011)
Deﬁnition Magnesium silicate is a synthetic
compound of which the molar ratio
of magnesium oxide to silicon
dioxide is approximately 2:5
Magnesium silicate (synthetic) is manufactured by the
precipitation reaction between sodium silicate and a
soluble magnesium salt. The aqueous suspension of
the precipitate is ﬁltered and the collected solid
washed, dried, classiﬁed for particle size and
packaged. The ﬁnest material is intended for use as
an anticaking agent and the coarser particles are for
use as a ﬁltering aid. The moisture content of the
material meant for use as an anticaking agent is kept
to less than 15%. Although magnesium silicate is of
variable composition, the molar ratio of MgO to SiO2
is approximately 2:5
Assay Content not less than 15%
of MgO and not less than
67% of SiO2 on the ignited
basis
Not less than 15% of MgO and not less than 67% of
SiO2, calculated on the ignited basis
Description Very ﬁne, white, odourless
powder, free from grittiness
Very ﬁne, white, odourless powder, free from
grittiness
Identiﬁcation Test for magnesium Passes test Passes test
Test for silicate Passes test Passes test
Solubility – Insoluble in water
pH 7–10.8
(10% slurry)
7–11 (1 in 10 slurry)
Purity
Loss on drying Not more than 15% (105°C, 2 h) Not more than 15% (for material used as an
anticaking agent (105°C, 2 h))
Loss on ignition Not more than 15% after
drying (1,000°C, 20 min)
Not more than 15% on the dried basis (900/1,000°C,
20 min)
Fluoride Not more than 10 mg/kg Not more than 10 mg/kg
Water-soluble salts Not more than 3% Not more than 3%
Free alkali Not more than 1% (as NaOH) Not more than 1% (as NaOH)
Arsenic Not more than 3 mg/kg –
Lead Not more than 5 mg/kg Not more than 5 mg/kg
Mercury Not more than 1 mg/kg –
Table 3: Speciﬁcations for magnesium trisilicate (E 553a(ii)) according to Commission Regulation
(EU)
Commission Regulation (EU) No 231/2012
Deﬁnition
Assay Content not less than 29.0% of MgO and not less than 65.0% of SiO2 both
on the ignited basis
Description Fine, white powder, free from grittiness
Identiﬁcation Test for magnesium Passes test
Test for silicate Passes test
pH 6.3–9.5 (5% slurry)
Purity
Loss on ignition Not less than 17% and not more than 34% (1,000°C)
Water-soluble salts Not more than 2%
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The Panel noted that according to Regulation 231/2012 calcium silicate (E 552), magnesium silicate
(E 553(i)) and magnesium trisilicate (E 553(ii)) are deﬁned as silicates with varying proportions of
oxides and silicon dioxide. The Panel considered that, in fact, silicates are not a mixture of oxides and
silicon dioxide. The Panel considered that this should be clariﬁed in the EU speciﬁcations.
The Panel noted that no minimum limit for hydrous magnesium silicate in E 553b is speciﬁed in the
EU speciﬁcations. According to Fiume et al. (2015), talc used in cosmetics consists of a minimum of
90% hydrous magnesium silicate with the rest consisting of naturally associated minerals such as
calcite, chlorite, dolomite, kaolin and magnesite (but no alpha-quartz or phlogopite, as in the EU
speciﬁcations for E 553b).
The Panel noted that impurities of the toxic elements arsenic, lead and mercury are accepted up to
concentrations of 3, 2 and 1 mg/kg according to the EU speciﬁcations for calcium silicate (E 552), up
to concentrations of 3, 5 and 1 mg/kg for magnesium silicate (E 553a(i)) and magnesium trisilicate,
(E 553a(ii)). For talc (E 553b), arsenic and lead are accepted up to concentrations of 10 and 2 mg/kg.
Contamination at such levels could have a signiﬁcant impact on the exposure to these metals, which is
Commission Regulation (EU) No 231/2012
Free alkali Not more than 1% (as NaOH)
Fluoride Not more than 10 mg/kg
Arsenic Not more than 3 mg/kg
Lead Not more than 5 mg/kg
Mercury Not more than 1 mg/kg
Table 4: Speciﬁcations for talc (E 553b) according to Commission Regulation (EU) No 231/2012 and
according to JECFA (2006)
Commission Regulation (EU)
No 231/2012
JECFA (2006)
Deﬁnition Naturally occurring form of hydrous
magnesium silicate containing varying
proportions of such associated minerals
as alpha-quartz, calcite, chlorite,
dolomite, magnesite, and phlogopite.
The product should be free of asbestos
Powdered, natural, hydrated magnesium
silicate containing varying proportions of
such associated materials as alpha-quartz,
calcite, chlorite, dolomite, magnesite and
phlogopite
Assay – –
Description Light, homogeneous, white or almost
white powder, greasy to the touch
Odourless, very ﬁne, white or greyish white
crystalline powder; unctuous, adheres
readily to the skin, free from grittiness
Identiﬁcation Infrared
absorption
spectrum
Characteristic peaks at
3,677, 1,018 and 669 cm1
Major peaks of a potassium bromide
dispersion of the sample at 3,677, 1,018
and 669 cm1
X-ray
diffraction
Peaks at 9.34/4.66/3.12 A Pattern of a random powder sample exhibits
reﬂections at d values of 9.34, 4.66 and
3.12 A
Solubility Insoluble in water
and ethanol
Insoluble in water and ethanol
Purity
Loss on drying Not more than 0.5% (105°C, 1 h) Not more than 0.5% (105°C, 1 h)
Acid soluble matter Not more than 6% Not more than 2.5%
Water-soluble matter Not more than 0.2% Not more than 0.2%
Acid soluble iron Not detectable Not detectable
Arsenic Not more than 10 mg/kg –
Lead Not more than 2 mg/kg Not more than 2 mg/kg
Asbestos (a) Free from asbestos as demonstrated by the
test for amphiboles and serpentines
(a): The provision for asbestos in the EU speciﬁcations is included in the deﬁnition of the food additive.
Re-evaluation of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
(E 553a(ii)) and talc (E 553b)
www.efsa.europa.eu/efsajournal 16 EFSA Journal 2018;16(8):5375
already close to the health-based guidance values or benchmark doses (lower conﬁdence limits)
established by EFSA (EFSA CONTAM Panel, 2009a,b, 2010, 2012a,b,c, 2014).
Considering the information presented in Section 3.1.1, the Panel considered that maximum limit
for aluminium, nickel and ﬂuoride should be included in the EU speciﬁcations for talc (E 553b).
The Panel noted that crystalline silica (alpha-quartz) may also be present as an associated mineral,
according to the EU speciﬁcations for talc (E 553b). The Panel noted that crystalline silica is a class 1
carcinogen by inhalation (IARC, 1997) and no maximum limit for quartz has been established in the EU
speciﬁcations for talc (E 553b).
3.1.3. Manufacturing process
Calcium silicate (E 552)
According to industry, the manufacturing process for calcium silicate (E 552) comprises the
following stages: dilution of raw materials, mixing and precipitation, solid–liquid ﬁltration/washing,
drying and packaging. Optionally, after the drying step, the product can be milled and/or granulated.
The substance is, manufactured either batchwise or via a continuous process. The starting materials
for the production of E 552 are diluted calcium chloride or calcium hydroxide and sodium silicates (e.g.
waterglass composed of Na2O:SiO2) (CEFIC, 2017a (Documentation provided to EFSA n. 4)).
When using calcium chloride and sodium silicate (waterglass) as starting materials, calcium silicate
is formed as a precipitate.
When using calcium hydroxide as a starting material, the calcium hydroxide is added to a slurry of
silicon dioxide, before or after the ﬁltration step. Calcium hydroxide reacts in situ in aqueous media
with silicon dioxide forming calcium silicate.
The calcium silicate suspension is ﬁltered and the ﬁltrate is washed to remove salts (e.g. sodium
chloride or sodium sulfate). Drying is performed according to different processes depending on the
characteristics required for the ﬁnal product.
After drying, the product is milled. During milling the particle size distribution and sieve residue
characteristics of the product are controlled.
Magnesium silicate (E 553a(i)) and magnesium trisilicate (E 553 a(ii))
According to information provided (CEFIC, 2017b (Documentation provided to EFSA n. 5)), both
magnesium silicate (E 553a(i) and magnesium trisilicate E 553a(ii) are manufactured either batchwise or
via a continuous process. The production steps include raw material preparation, synthesis, drying,
packaging, storage and shipment. After the drying step, the products may further be milled or granulated.
The raw materials for the production of E 553a(i) and E 553a(ii) are magnesium salts (e.g.
magnesium sulfate, magnesium chloride) and aqueous alkali metal solution (sodium silicate solution).
In the reaction of magnesium salt with sodium silicate (waterglass), magnesium silicate is formed in
a process-controlled, double replacement reaction in water.
The suspension obtained after reaction is ﬁltered using various solid/liquid ﬁlters. After ﬁltration,
salts are washed-out. The silicate is dried, and further processed by milling or granulation depending
on the required properties of the ﬁnal product.
Talc (E 553b)
Talc is a naturally occurring substance. Deposits of talc are found in several countries, including China,
United States, India, Brazil and France; different types of deposit occur depending on the way in which
the talc was formed, and each type contains a different group of associated minerals (IARC, 1997).
The purity of commercial products can be improved by either dry or wet processing. In both cases,
talc ore is crushed and ground to a ﬁne material before being mixed with water and a frothing agent
(often a low-molecular-weight alcohol). Air is bubbled through the suspension which results in ﬂotation
and sequestration of talc particles and therefore removal of hydrophilic non-talc impurities. This
process may be repeated several times to increase talc purity. Magnetic separation or acid washing
may be used to remove iron-bearing minerals, soluble salts and metals. Finally, the talc is ﬁltered,
washed and dried, and may be heat sterilised (CIR, 2013; Fiume et al., 2015).
Talc (E 553b) is a white mineral powder produced after grinding talc that has been mined
(EUROTALC, 2018b (Documentation provided to EFSA n. 12)).
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3.1.4. Methods of analysis in food
The Panel noted that silicates may be determined in food via measuring the total silicon. Analytical
methods for measuring total silicon in food were described in the EFSA opinion on the re-evaluation of
silicon dioxide (E 551) (EFSA ANS Panel, 2018). Nevertheless, when this principle is followed, it cannot
be differentiated whether the measured silicon content originates from the added silicates, silicon
dioxide or the naturally occurring silicon in food.
General methods for the analysis of silicates were reviewed by (Rashid et al., 2011). These relate
mainly to the analysis of aqueous samples.
Information on a method for the detection of talc (E 553b) in food or beverage samples was
submitted by industry (EUROTALC, 2012 (Documentation provided to EFSA n. 10)). This involves
burning a sample of the food/beverage in a furnace for 1 h at 500°C to remove organic components,
followed by X-ray diffraction examination of a sample of the ash to identify and quantify the talc. No
information on the limit of detection of the method has been provided.
The Panel noted that no speciﬁc analysis for the presence of silicates or their particles in food have
been reported in the literature.
3.1.5. Stability of the substances, and reaction and fate in food
According to industry (CEFIC, 2017a (Documentation provided to EFSA n. 4)), calcium silicate is
formed by replacing protons (H+) of silanol groups with calcium ions (Ca2+) in alkaline conditions. This
is a reversible reaction and in acidic conditions silanol groups are re-formed and Ca2+ ions released.
3.2. Authorised uses and use levels
Maximum levels of calcium silicate (E 552), magnesium silicate (E 553a), talc (E 553b) and for the
group ‘silicon dioxide-silicates (E 551-553)’ have been deﬁned in Annex II to Regulation (EC) No 1333/2008
on food additives, as amended. In this document, these levels are named maximum permitted levels
(MPLs).
Currently, calcium silicate (E 552), magnesium silicate (E 553a) and talc (E 553b) are authorised
food additives in the EU with MPLs ranging from 5,400 to 30,000 mg/kg in 13 food categories and at
quantum satis (QS) in 15 food categories as listed in Table 5.
In this opinion, exposure to calcium silicate (E 552), magnesium silicate (E 553a) and talc (E 553b)
as a group ‘silicates (E 552–553)’ was calculated.
Table 5: MPLs of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
(E 553a(ii)) and talc (E 553b) in foods according to the Annex II to Regulation (EC) No
1333/2008
Food category
number
Food categories
name
E-Number/
group
Name
Restrictions/
exceptions
MPL (mg/L
or mg/kg as
appropriate)
0 Food additives
permitted in all
categories of foods
E 551–553 Silicon
dioxide –
silicates
Only foods in dried
powdered form (i.e.
foods dried during
the production
process, and
mixtures thereof),
excluding foods listed
in table 1 of Part A of
Annex II
10,000
0 Food additives
permitted in all
categories of foods
E 551–553 Silicon
dioxide –
silicates
Only foods in tablet
and coated tablet
form, excluding the
foods listed in table 1
of Part A of Annex II
Quantum satis
01.7.2 Ripened cheese E 551–553 Silicon
dioxide –
silicates
Only sliced or grated
cheese hard and
semi-hard cheese
10,000
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Food category
number
Food categories
name
E-Number/
group
Name
Restrictions/
exceptions
MPL (mg/L
or mg/kg as
appropriate)
01.7.5 Processed cheese E 551–553 Silicon
dioxide –
silicates
10,000
01.7.6 Cheese products
(excluding products
falling in category 16)
E 551–553 Silicon
dioxide –
silicates
Only sliced or grated
hard and semi-hard
products
10,000
01.8 Dairy analogues,
including beverage
whiteners
E 551–553 Silicon
dioxide –
silicates
Only sliced or grated
cheese analogues
and processed
cheese analogue;
beverage whiteners
10,000
02.2.2 Other fat and oil
emulsions including
spreads as deﬁned by
Council Regulation
(EC) No 1234/2007
and liquid emulsions
E 551–553 Silicon
dioxide –
silicates
Only tin greasing
products
30,000
02.3 Vegetable oil pan
spray
E 551–553 Silicon
dioxide –
silicates
Only tin greasing
products
30,000
05.2 Other confectionery
including breath
refreshening
microsweets
E 551–553 Silicon
dioxide –
silicates
Surface treatment
only
Quantum satis
05.3 Chewing gum E 552 Calcium
silicate
Surface treatment
only
Quantum satis
05.3 Chewing gum E 553a Magnesium
silicate
Surface treatment
only
Quantum satis
05.3 Chewing gum E 553b Talc Quantum satis
05.4 Decorations, coatings
and ﬁllings, except
fruit based ﬁllings
covered by category
4.2.4
E 551–553 Silicon
dioxide –
silicates
Surface treatment
only
Quantum satis
06.1 Whole, broken, or
ﬂaked grain
E 553b Talc Only rice Quantum satis
08.2 Meat preparations as
deﬁned by Regulation
(EC) No 853/2004
E 553b Talc Only surface
treatment of
sausages
Quantum satis
08.3.1 Non-heat-treated meat
products
E 553b Talc Only surface
treatment of
sausages
Quantum satis
08.3.2 Heat–treated meat
products
E 553b Talc Only surface
treatment of
sausages
Quantum satis
10.2 Processed eggs and
egg products
E 553b Talc Only on the surface
of unpeeled coloured
boiled eggs
5,400
11.1 Sugars and syrups as
deﬁned by Directive
2001/111/EC
E 551–553 Silicon
dioxide –
silicates
Only dried powdered
foods
10,000
11.1 Sugars and syrups as
deﬁned by Directive
2001/111/EC
E 551–553 Silicon
dioxide –
silicates
Only foods in tablet
and coated tablet
form
Quantum satis
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According to Annex III, Part 1, calcium silicate (E 552) is authorised as a carrier in emulsiﬁers and
colours at QS, and talc (E 553b) is authorised as a carrier in colours at a maximum level of 50 mg/kg
in the colour preparation.
According to Annex III, Part 2 of Regulation (EC) No 1333/2008, calcium silicate (E 552) is
authorised as a food additive other than a carrier in dry powdered preparations of emulsiﬁers at a
maximum level of 50,000 mg/kg in the preparation. Calcium silicate (E 552), magnesium silicate
(E 553a) and talc (E 553b) are authorised as food additives in food additives only in dry powdered
preparations of polyols at a maximum level of 10,000 mg/kg in the preparation.
In addition, according to Annex III, Part 5, Section A of Regulation (EC) No 1333/2008, calcium
silicate (E 552) is authorised as a food additive in dry powdered preparations of all nutrients, except
nutrients intended to be used in foods for infant and young children as listed in point 13.1 of Part E of
Annex II, at a maximum level of 50,000 mg/kg in the dry preparation (singly or in combination with
silicon dioxide (E 551)).
The Panel noted that calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
(E 553a(ii)) and talc (E 553b) are authorised mainly for use in dried products or as a surface treatment.
3.3. Exposure data
3.3.1. Reported use levels or data on analytical levels of calcium silicate (E 552),
magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc
(E 553b)
Most food additives in the EU are authorised at a speciﬁc MPL. However, a food additive may be
used at a lower level than the MPL. Therefore, information on actual use levels is required for
Food category
number
Food categories
name
E-Number/
group
Name
Restrictions/
exceptions
MPL (mg/L
or mg/kg as
appropriate)
11.4.2 Table top sweeteners
in powder form
E 551–553 Silicon
dioxide –
silicates
10,000
11.4.3 Table top sweeteners
in tablets
E 551–553 Silicon
dioxide –
silicates
Quantum satis
12.1.1 Salt E 551–553 Silicon
dioxide –
silicates
10,000
12.1.2 Salt substitutes E 551–553 Silicon
dioxide –
silicates
20,000
12.2.2 Seasonings and
condiments
E 551–553 Silicon
dioxide –
silicates
Only seasoning 30,000
17.1(a) Food supplements
supplied in a solid
form including
capsules and tablets
and similar forms,
excluding chewable
forms
E 551–553 Silicon
dioxide –
silicates
Quantum satis
17.2(a) Food supplements
supplied in a liquid
form
E 551–553 Silicon
dioxide –
silicates
Quantum satis
17.3(a) Food supplements
supplied in a syrup-
type or chewable form
E 551–553 Silicon
dioxide –
silicates
Quantum satis
MPL: maximum permitted level.
(a): FCS 17 refers to food supplements as deﬁned in Directive 2002/46/EC of the European Parliament and of the Council
excluding food supplements for infants and young children.
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performing a more realistic exposure assessment, especially for those food additives, which are
authorised according at QS in all or part of the authorised food categories.
In the framework of Regulation (EC) No 1333/2008 on food additives and of Commission
Regulation (EU) No 257/2010 regarding the re-evaluation of approved food additives, EFSA issued a
public call(s)17 for occurrence data (usage level and/or analytical data) on calcium silicate (E 552),
magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b). In response to this
public call, updated information on the actual use levels of these food additives in foods was made
available to EFSA by industry. No analytical data on the concentration of these additives in foods were
made available by the Member States.
Summarised data on reported use levels in foods provided by industry
Industry provided EFSA with data on use levels (n = 292) of calcium silicate (E 552), magnesium
silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b) in foods for 7 out of the 28
food categories in which these food additives are authorised. Most of the data provided to EFSA
referred to talc (E 553b) (n = 287).
Updated information on the actual use levels of silicates (E 552–553) in foods was made available
to EFSA by Dr Loges Naturheilkunde neu entdecken, Grupo AC MARCA, European Snacks Association/
SNACMA (ESA), Association of the European Self-Medication Industry (AESGP), Specialised Nutrition
Europe (SNE), Food Drink Europe (FDE), Food Supplements Europe (FSE), International Chewing Gum
Association (ICGA) and EUROTALC.
The Panel noted that two use levels on food supplements referred to niche products. Since other
use levels were available for this food category, the Panel excluded them from further analysis.
Appendix A provides the data on the use levels of silicates (E 552–553) in foods as reported by
industry.
3.3.2. Summarised data extracted from the Mintel’s Global New Products
Database
The Mintel’s GNPD is an online database which monitors new introductions of packaged goods in
the market worldwide. It contains information of over 2.5 million food and beverage products of which
more than 900,000 are or have been available on the European food market. Mintel started covering
EU’s food markets in 1996, currently having 20 out of its 28 member countries and Norway presented
in the Mintel GNPD.18
For the purpose of this Scientiﬁc Opinion, THE Mintel’s GNPD19 was used for checking the labelling
of food and beverages products and food supplements for silicates (E 552–553) within the EU’s food
market as the database contains the compulsory ingredient information on the label.
According to the Mintel’s GNPD, silicates (E 552–553) were labelled on more than 1,000 products
between January 2013 and January 2018. In 89% of the foods, the food additive labelled was talc
(E 553b). The main food category labelled with one of these food additives is food supplements.
Appendix B lists the percentage of the food products labelled with silicates (E 552–553) out of the
total number of food products per food subcategory according to the Mintel’s GNPD food classiﬁcation.
The percentages ranged from less than 0.1% in most of food subcategories up to 8% in the Mintel’s
GNPD food subcategory ‘Vitamins & Dietary Supplements’. The average percentage of foods labelled to
contain calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and
talc (E 553b) was 0.2%. For ﬁve food categories authorised to contain silicates (E 552–553) and found
to be labelled with these food additives in the Mintel’s GNPD, no data were submitted (meat products,
sugar and syrups, and seasonings).
For ripened cheese and processed cheese, which are food categories authorised to contain silicates,
no food items were found in the Mintel’s GNPD, but data were submitted to EFSA.
For other food categories authorised to contain silicates (rice, table-top sweeteners, dairy
analogues, other fat and oil emulsions, vegetable oil pan spray, processed eggs and egg products and
salt substitutes), no foods were found in the Mintel’s GNPD nor were data submitted to EFSA.
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3.3.3. Food consumption data used for exposure assessment
EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (Comprehensive
Database) has been populated with national data on food consumption at a detailed level. Competent
authorities in the European countries provide EFSA with data on the level of food consumption by the
individual consumer from the most recent national dietary survey in their country (cf. Guidance of
EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a). Consumption surveys added in the Comprehensive database in 2015 were
also taken into account in this assessment.20
The food consumption data gathered by EFSA were collected by different methodologies and thus
direct country-to-country comparisons should be interpreted with caution. Depending on the food category
and the level of detail used for exposure calculations, uncertainties could be introduced owing to possible
subjects’ underreporting and/or misreporting of the consumption amounts. Nevertheless, the EFSA
Comprehensive Database includes the currently best available food consumption data across Europe.
Food consumption data from the following population groups were used for the exposure
assessment: infants, toddlers, children, adolescents, adults and the elderly. For the present assessment,
food consumption data were available from 33 different dietary surveys carried out in 19 European
countries (Table 6).
Consumption records were codiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
Nomenclature from the FoodEx classiﬁcation system has been linked to the food categorisation system
(FCS) as presented in Annex II of Regulation (EC) No 1333/2008, part D, to perform exposure
estimates. In practice, the FoodEx food codes were matched to the FCS food categories.
Food categories considered for the exposure assessment of silicates
The food categories in which the use of silicates (E 552–553) is authorised were selected from the
nomenclature of the EFSA Comprehensive Database (FoodEx classiﬁcation system), at the most
detailed level possible (up to FoodEx Level 4) (EFSA, 2011b).
Some food categories for which MPLs were available and/or use levels were submitted are not
referenced in the EFSA Comprehensive Database and could therefore not be taken into account in the
exposure assessment. This was the case for ﬁve food categories (Appendix C) and may have resulted
Table 6: Population groups considered for the exposure estimates of silicates (E 552–553)
Population Age range
Countries with food consumption surveys covering
more than 1 day
Infants From more than 12 weeks up to
and including 11 months of age
Bulgaria, Denmark, Finland, Germany, Italy, UK
Toddlers(a) From 12 months up to and
including 35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany, Italy,
Netherlands, Spain, UK
Children(b) From 36 months up to and
including 9 years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland,
France, Germany, Greece, Italy, Latvia, Netherlands, Spain,
Sweden, UK
Adolescents From 10 years up to and
including 17 years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland,
France, Germany, Italy, Latvia, Netherlands, Spain, Sweden,
UK
Adults From 18 years up to and
including 64 years of age
Austria, Belgium, Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Romania,
Spain, Sweden, UK
The elderly(b) From 65 years of age and older Austria, Belgium, Denmark, Finland, France, Germany, Hungary,
Ireland, Italy, Romania, Netherlands, Sweden, UK
(a): ‘Toddlers’ in the EFSA Comprehensive Database corresponds to ‘young children’ in Regulations (EC) No 1333/2008 and (EU)
No 609/2013.
(b): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
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in an underestimation of the exposure. The food categories which were not taken into account were
(in ascending order of the FCS codes):
• 01.7.6 Cheese products (excluding products falling in category 16)
• 02.2.2 Other fat and oil emulsions including spreads as deﬁned by Council Regulation (EC) No
1234/2007 and liquid emulsions, only tin greasing products
• 02.3 Vegetable oil pan spray, only tin greasing products
• 10.2 Processed eggs and egg products, only on the surface of unpeeled coloured boiled eggs
• 12.1.2 Salt substitutes.
For the following food categories, the restrictions/exceptions which apply to the use of silicates
(E 552–553) could not be taken into account, and therefore the whole food category was considered
in the exposure assessment. This applied to four food categories (Appendix C) and may have resulted
in an overestimation of the exposure:
• 01.7.2 Ripened cheese, only sliced or grated cheese hard and semi-hard cheese. The full food
category was taken into account because the restriction could represent a large part of the
consumed food category.
• 01.8 Dairy analogues, including beverages whiteners, only sliced or grated cheese analogues
and processed cheese analogue; beverages whiteners. The full food category was taken into
account because the restriction could represent a large part of the consumed food category.
• 11.1 Sugars and syrups as deﬁned by Directive 2001/111/EC, only dried powdered foods.
• 11.1 Sugars and syrups as deﬁned by Directive 2001/111/EC, only foods in tablet and coated
tablet form.
These last two food categories represent most of the foods belonging to FC 11.1 and were
therefore considered completely. This uncertainty was furthermore only relevant for the regulatory
maximum level exposure assessment scenario. In the reﬁned scenarios, three of these four food
categories were not included (except FC 01.7.2), due to lack of use levels (Appendix A).
The FCs 17.1/17.2/17.3 Food supplements, in solid, liquid, syrup-type or chewable form, the form
cannot be differentiated and the same use level was applied to the whole FC 17. The FCs were taken
into account only in the speciﬁc scenario on food supplements and were not included in the regulatory
exposure scenario.
It has to be noted that silicates (E 552–553) are authorised in FC 0, meaning in ‘all categories of
foods excluding foods for infants and young children, except where speciﬁcally provided for’. In the
case of silicates, two restrictions apply to this food category:
• only foods in dried powdered form (i.e. foods dried during the production process, and
mixtures thereof), excluding foods listed in Table 1 of Part A of Annex II,
• only foods in tablet and coated tablet form, excluding the foods listed in Table 1 of Part A of
Annex II.
Use levels of E 552 were provided for FC 15 Ready-to-eat savouries and snacks, and ‘coated
peanut cracker’ despite not being authorised in this FC. However, its use in FC 15 can be explained by
its authorisation in FC 0. This was also true for the use level provided for ‘chocolate bar’. These use
levels were respectively mapped to the consumption of FCs 15.1, 15.2 and chocolate coating (FC 05.4)
in all exposure scenarios. This is in line with Mintel’s GNPD as nuts and snacks were found to be
labelled with silicates (Appendix B).
Four food categories (06.1, 08.2, 08.3.1 and 08.3.2) could not be taken into account as they are
authorised at QS and no use levels were reported by industry.
Considering all, in total 16 food categories were included in the regulatory maximum level exposure
assessment scenario.
Considering only the food categories for which use levels were provided, nine food categories were
included in the reﬁned exposure assessment to silicates (E 552–553), including the two FCs 15.1 and
15.2 and excluding exposure via food supplements (Appendix C).
Compared to the reﬁned scenario, three additional food categories (in total 12) were considered in
the food supplements scenario.
For the remaining food categories, the reﬁnements considering the restrictions/exceptions as set in
Annex II to Regulation No 1333/2008 were applied.
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3.4. Exposure to silicates from their use as food additives
The Panel estimated the chronic dietary exposure to silicates (E 552–553) for the following
population groups: infants, toddlers, children, adolescents, adults and the elderly. Dietary exposure to
silicates was calculated by multiplying concentrations of silicates (E 552–553) per food category
(Appendix C) with their respective consumption amount per kilogram body weight for each individual
in the Comprehensive Database. The exposure per food category was subsequently added to derive an
individual total exposure per day. These exposure estimates were averaged over the number of survey
days, resulting in an individual average exposure per day for the survey period. Dietary surveys with
only one day per subject were excluded as they are considered as not adequate to assess repeated
exposure.
This was carried out for all individuals per survey and per population group, resulting in
distributions of individual exposure per survey and population group (Table 6). On the basis of these
distributions, the mean and 95th percentile of exposure were calculated per survey and per population
group. The 95th percentile of exposure was only calculated for those population groups with a
sufﬁciently large sample size (EFSA, 2011a). Therefore, in the present assessment, the 95th percentile
of exposure for infants from Italy and for toddlers from Belgium, Italy and Spain were not estimated.
Exposure assessment to silicates (E 552–553) was carried out by the ANS Panel based on two
different sets of concentration data: (1) MPLs as set down in the EU legislation (deﬁned as the
regulatory maximum level exposure assessment scenario) and maximum reported use level for food
categories with a permitted use at QS; and (2) reported use levels (deﬁned as the reﬁned exposure
assessment scenario). These two scenarios are discussed in detail below.
These scenarios do not consider the intake of food supplements. This exposure source is covered in
an additional scenario detailed below (food supplements consumers only scenario).
A possible additional exposure from the use of silicates as food additives in food additives and
nutrients in accordance with Annex III to Regulation (EC) No 1333/2008 (Parts 1, 2 and 5A) was not
considered in any of the exposure assessment scenarios.
3.4.1. Regulatory maximum level exposure assessment scenario
The regulatory maximum level exposure assessment scenario is based on the MPLs as set in Annex
II to Regulation (EC) No 1333/2008 and listed in Table 2. For silicates, the MPLs used in the
assessment are listed in Table 5. For the food categories authorised at QS, the maximum reported use
levels when available was used (Appendix C).
The Panel considers the exposure estimates derived with this scenario as the most conservative
since it is assumed that that the population will be exposed to food additives present in food at the
MPL/maximum reported use level over a longer period of time.
3.4.2. Reﬁned exposure assessment scenario
The reﬁned exposure assessment scenario is based on use levels reported by food industry. This
exposure scenario can consider only food categories for which these data were available to the Panel.
Appendix C summarises the concentration levels of silicates (E 552–553) used in the reﬁned
exposure assessment scenario. Based on the available data set, the Panel calculated two reﬁned
exposure estimates based on two model populations:
• The brand-loyal consumer scenario: It was assumed that a consumer is exposed long-term to
silicates (E 552–553) present at the maximum reported use level for one food category. This
exposure estimate was calculated as follows:
 Combining food consumption with the maximum of the reported use levels for the main
contributing food category at the individual level.
 Using the mean of the typical reported use levels for the remaining food categories.
• The non-brand-loyal consumer scenario: It was assumed that a consumer is exposed long-
term to silicates present at the mean reported use levels in food. This exposure estimate was
calculated using the mean of the typical reported use levels for all food categories.
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3.4.3. Food supplement consumers only scenario
Silicates are authorised in FC 17 (Food supplements as deﬁned in Directive 2002/46/EC excluding
food supplements for infants and young children). As exposure via food supplements may deviate
largely from that via food, and the number of food supplement consumers may be low depending on
populations and surveys, an additional scenario was calculated in order to reﬂect additional exposure
to silicates from the intake of food supplements. This additional exposure was estimated assuming that
consumers of food supplements were exposed to silicates present at the maximum reported use levels
in food supplements on a daily basis. For the remaining food categories, the mean of the typical
reported use levels of silicates was used.
As FC 17 does not consider food supplements for infants and toddlers as deﬁned in the legislation,
exposure to silicates from food supplements was not estimated for these two population groups.
This scenario included 12 food categories (Appendix C).
3.4.4. Dietary exposure to silicates
Table 7 summarises the estimated exposure to silicates (E 552–553) from their use as food
additives in six population groups (Table 6) according to the different exposure scenarios. Detailed
results per population group and survey are presented in Appendix D.
In the regulatory maximum level exposure assessment scenario, the mean exposure to silicates
(E 552–553) from their use as food additives ranged from 2 mg/kg bw per day in adults to 34.6 mg/kg
bw per day in toddlers. The 95th percentile of exposure to silicates (E 552–553) ranged from 6.9 mg/kg
bw per day in adults to 113.8 mg/kg bw per day in children.
In the brand-loyal scenario, the mean exposure to silicates (E 552–553) from their use as food
additives ranged from 0.1 mg/kg bw per day in infants to 27.5 mg/kg bw per day in children. The high
exposure to silicates ranged from 0 mg/kg bw per day in infants to 110 mg/kg bw per day in children.
In the non-brand-loyal scenario, the mean exposure to silicates (E 552–553) from their use as food
additives ranged from below 0.1 mg/kg bw per day in infants to 18.4 mg/kg bw per day in toddlers.
The 95th percentile of exposure to silicates (E 552–553) ranged from below 0 mg/kg bw per day in
infants to 41.9 mg/kg bw per day in children.
For the food supplements consumers only scenario, the mean exposure to silicates (E 552–553)
from their uses as food additives ranged between 5 mg/kg bw per day for adults and the elderly to
31 mg/kg bw per day for children. The 95th percentile of exposure to silicates ranged between 14 and
46 mg/kg bw per day for the elderly (Appendix F).
Table 7: Summary of dietary exposure to silicates (E 552–553) from their use as food additives in the
regulatory maximum level exposure assessment scenario and in the reﬁned exposure
scenarios, in six population groups (minimum–maximum across the dietary surveys in mg/kg
bw per day)
Infants
(12 weeks–
11 months)
Toddlers
(12–35
months)
Children
(3–9
years)
Adolescents
(10–17
years)
Adults
(18–64
years)
The elderly
(≥ 65 years)
Regulatory maximum level exposure assessment scenario
 Mean 2.1–16.2 9.1–24.9 4.1–34.6 2.7–24.3 2.0–14.6 2.6–10.0
 95th percentile 9.3–39.2 27.0–72.9 14.6–113.8 9.1–73.2 6.9–51.8 7.1–18.4
Reﬁned estimated exposure assessment scenario
Brand-loyal scenario
 Mean 0.1–10.5 2.2–19.9 1.1–27.5 0.7–17.8 0.3–11.7 0.7–6.7
 95th percentile 0–21.4 12.9–65.0 4.5–110.4 3.9–64.9 1.7–46.6 3.0–14.7
Non-brand-loyal scenario
 Mean 0.1–10.5 1.0–18.4 0.6–13.2 0.6–9.4 0.2–6.9 0.5–4.7
 95th percentile 0–21.4 4.9–27.3 2.7–41.9 2.9–24.1 1.3–18.4 2.2–11.9
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Main food categories contributing to exposure to silicates for the general population
In the regulatory maximum level exposure assessment scenario, the main contributing food
categories to the total mean exposure to silicates (E 552–553) were FC 01.7.2 Ripened cheese and FC
11.1 Sugars and syrups for all population groups.
For infants, adults and the elderly, the main contributing food categories in both the brand-loyal
and non-brand-loyal scenario were FC 01.7.2 Ripened cheese and FC 01.7.5 Processed cheese.
For toddlers, the main contributing food categories in both the brand-loyal and non-brand-loyal
scenario were FC 01.7.2 Ripened cheese, FC 01.7.5 Processed cheese and FC 05.1 Cocoa and
Chocolate products as covered by Directive 2000/36/EC. In the brand-loyal scenario also FC 05.2 Other
confectionery including breath freshening microsweets was an important contributing food category.
For children, the main contributing food categories in the brand-loyal were FC 01.7.2 Ripened
cheese, FC 05.2 Other confectionery including breath freshening microsweets and FC 05.3 Chewing
gum. In the non-brand-loyal, the main contributing food categories were FC 01.7.2 Ripened cheese, FC
05.1 Cocoa and Chocolate products as covered by Directive 2000/36/EC and FC 05.3 Chewing gum.
For adolescents, the main contributing food categories in the brand-loyal scenario were FC 01.7.2
Ripened cheese and FC 05.3 Chewing gum. In the non-brand-loyal, the main contributing food
categories were FC 01.7.2 Ripened cheese, FC 01.7.5 Processed cheese and FC 05.3 Chewing gum.
Appendix E summarises the contributing food categories for the regulatory maximum level and the
reﬁned exposure assessment scenario.
3.4.5. Uncertainty analysis
Uncertainties in the exposure assessment of silicates (E 552–553) have been discussed above. In
accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary exposure
assessment (EFSA, 2007), the following sources of uncertainties have been considered and
summarised in Table 8.
Table 8: Qualitative evaluation of inﬂuence of uncertainties on the dietary exposure estimate of
silicates (E 552–553)
Sources of uncertainties Direction(a)
Consumption data: different methodologies/representativeness/underreporting/misreporting/no
portion size standard
+/–
Use of data from food consumption surveys covering only a few days to estimate high
percentiles (95th) long-term (chronic) exposure
+
Correspondence of reported use levels to the food items in the EFSA Comprehensive Food
Consumption Database: uncertainties to which types of food the levels refer
+/–
Uncertainty in possible national differences in use levels within food categories +/–
Concentration data:
• use levels considered applicable to all foods within the entire food category, whereas on
average 0.2% of the foods (according to the Mintel’s GNPD), belonging to food categories
with foods labelled with silicates (E 552–553), was labelled with at least one of these
additives
+
Food categories selected for the exposure assessment: exclusion of food categories with MPLs
and/or use levels due to missing FoodEx linkage (n = 5/28 food categories authorised according
to Annex II)
–
Food categories selected for the exposure assessment: inclusion of food categories without
considering the restriction/exception (n = 4 food categories authorised according to Annex II in
the regulatory maximum level exposure assessment scenario and n = 1 in the reﬁned exposure
assessment scenario)
+
Food categories selected for the exposure assessment: no concentration data for certain food
categories which were therefore not considered in the exposure estimates (n = 4 for the
regulatory scenario/13 food categories for reﬁned scenario)
–
Foods which may contain the food additive according to Annex III to Regulation (EC)
No 1333/2008 not taken into account
–
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Silicates (E 552–553) are authorised in 28 food categories (Table 2). Reported use levels were only
available for seven food categories in the reﬁned scenario.
The Panel noted that information from the Mintel GNPD (Appendix B) showed that the main food
subcategories, categorised according to the Mintel GNPD nomenclature (i.e. Vitamins & Dietary
Supplements, confectionary, chewing gums), labelled to contain silicates (E 552–553) were included in
the current exposure assessment. On the other hand, some foods in which the use of silicates
(E 552–553) is authorised but for which no data were submitted, were labelled to contain silicates
(E 552–553) according to the Mintel’s GNPD (e.g. meat products, sugar and syrups). This represents
at the maximum 2.5% of all food products within the food category (Appendix B).
The Panel also noted that no foods belonging to the main contributing food category in all
population groups i.e. ripened cheese, were labelled according to the Mintel GNPD. Only one use level
was reported for ripened cheese.
Furthermore, the Mintel’s GNPD showed that the maximum percentage of foods per food
subcategory labelled to contain silicates (E 552–553) was 8.4% for ‘Vitamins & Dietary Supplements’.
The average percentage of foods labelled to contain silicates (E 552–553) was 0.2%. In the
assessment, it was assumed that all foods belonging to the considered food categories contained
silicates (E 552–553) as food additives.
Given that the information from the Mintel’s GNPD reﬂects the use levels reported by industry to a
large extent, and that it was assumed that all foods belonging to the considered food categories
contained silicates (E 552–553), the Panel considered overall that the uncertainties identiﬁed would, in
general, result in an overestimation of the exposure to silicates (E 552–553) from their use as food
additives according to Annex II in all scenarios in European countries considered in the EFSA European
database. The Panel noted that food categories which may contain silicates (E 552–553) due to carry-
over (Annex III, Part 1, 2, 5) were not considered in the current exposure assessment.
3.4.6. Exposure to silicates from other sources
The Panel noted that magnesium trisilicate may be used with other ingredients to treat ulcer
dyspepsia and non-erosive gastroesophageal reﬂux as an over-the-counter therapeutic (Martindale
online). A single tablet of ‘magnesium trisilicate mixture’ (250 mg magnesium trisilicate, 250 mg
magnesium carbonate, 250 mg sodium hydrogen carbonate) may be taken as a single dose up to
1,000 mg magnesium trisilicate (14.3 mg/kg bw per dose). However, it may be taken ad libitum since
no maximum dose is indicated.
Calcium silicate, magnesium silicate, magnesium trisilicate and talc are permitted as ingredients in
cosmetic products and as an excipient for drugs.
Data to calculate the exposure via all these sources were not available to the Panel and therefore
the exposure resulting from these other sources could not be taken into account in this opinion.
3.5. Biological and Toxicological data
The Panel noted that:
• Some silicates are known to have effects on the lungs when inhaled (IARC 1997). This route of
exposure is not representative of the exposure of consumers to a food additive and therefore
these data were not considered in this evaluation.
• Data obtained with test samples that contained asbestos ﬁbres were not considered in this
evaluation because asbestos must not be present in the food additives (E 552, E 553b) according
to the current EU speciﬁcations and therefore these data were considered not relevant.
Sources of uncertainties Direction(a)
Regulatory maximum level exposure assessment scenario:
• exposure calculations based on the MPL/maximum reported use levels according to Annex
II to Regulation (EC) No 1333/2008
+
Reﬁned exposure assessment scenarios:
• exposure calculations based on the maximum or mean levels (reported use from industries) +/–
(a): +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of
exposure.
Re-evaluation of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
(E 553a(ii)) and talc (E 553b)
www.efsa.europa.eu/efsajournal 27 EFSA Journal 2018;16(8):5375
• Data regarding the effect of ‘talc’ on the incidence of ovarian cancer were not considered in
this evaluation because they are associated with exposure to talc via a route of exposure
(topical) which is not representative of its use as a food additive.
The Panel noted that in some studies (especially those conducted in the 1960–1970s) while the
authors reported analysis of ‘silica’ or ‘silicon dioxide’ content, analytical methods available at the time
were only capable of measuring silicon. The Panel considered that while this was expressed as silica or
silicon dioxide by the authors, it was not possible to determine whether it was silica or silicon that was
measured.
The Panel noted that many toxicity studies on calcium silicate reported in this opinion have been
performed in the 1960s using Silene EF, described as hydrated calcium silicate consisting of 64% silicon
dioxide, 18% calcium oxide; 0.6% aluminium oxide; 0.1% magnesium oxide; and 1.5% sodium chloride
with an average particle size of 30 nm (Columbia-Southern Chemical Corporation, 1953 (Documentation
provided to EFSA n. 8)). According to industry (CEFIC, 2018b (Documentation provided to EFSA n. 7)),
Silene EF was not sold for use as a food additive at that time and is not produced any longer. Although a
complete characterisation was not available, the percentage of calcium silicate- expressed as silicon
dioxide and calcium oxide- complied with the EU speciﬁcations for E 552. Therefore, the Panel considered
that the available toxicity studies could be used for the assessment of calcium silicate.
3.5.1. Absorption, distribution, metabolism and excretion
Animal studies
Calcium silicate
No information on absorption, metabolism and excretion was available; however some information
on distribution and accumulation could be obtained from a 2-year feeding study using Carworth Farm
rats (6 animals/sex per group; 3 weeks old). Animals were fed 1.0%, 5.0%, 7.5% or 10% (w/w)
(equivalent to 500, 2,500, 3,750 and 5,000 mg/kg bw per day) calcium silicate (Silene EF) in their
diets (Hazelton Laboratory, 1956 (Documentation provide to EFSA n 18)). At the end of the dosing
period, animals were sacriﬁced and tissue samples from the kidney, liver, spleen, cardiac muscle,
skeletal muscle and testes of three of the animals were sampled and pooled. There was a dose-related
increase of ‘silicon dioxide’ in the liver (5% concentration: males, 2-fold background; females, no or
slight increase; 10% concentration: males and females, 3-fold background), and in the kidney (5%
concentration: males, 3-fold background; females, no or slight increase; 10% concentration: males,
20-fold background; females, 15-fold background), but not in the other organs tested.
Magnesium silicate
No studies were available.
Magnesium trisilicate
Urinary excretion of silicon following oral ingestion of magnesium trisilicate has been investigated in
male Sprague–Dawley Cox rats (3 animals per group) (Benke and Osborn, 1979). Following a 17- to 18-h
fasting period, the animals were dosed by gavage with a single dose of 0, 40, 200 or 1,000 mg/kg bw of
magnesium trisilicate. Control animals (4–6 animals; 240–260 g) were administered water. Urine was
collected for four consecutive 24-h periods. Silicon excretion was most rapid during the ﬁrst 24 h after
dosing. The total amount of silicon excreted as a proportion of the total dose was 16.8% in the group
administered 40 mg magnesium trisilicate/kg bw. This decreased to 5.1% in the 200 mg/kg bw group,
and 1.5% in the 1,000 mg/kg bw group. According to the authors, the excretion of silicon from
magnesium trisilicate was limited, suggesting that either the process of absorption or excretion became
saturated. The Panel agreed with this conclusion.
Talc
Mice
Mice of the LACA strain (4 female animals; age not stated) were given a single oral dose (40 mg/kg
bw per day) of 3H-labelled talc (synthetically produced magnesium hydrogen metasilicate) by gavage
(Phillips et al., 1978). Two animals were then killed at 6 and 24 h after dosing. Urine and faeces were
collected, and the radioactivity was determined in the urine, combined faeces and large intestine,
combined stomach and small intestine, and in the carcass. The entire radioactivity was detected in the
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gastrointestinal tract and faeces at 6 and 24 h. No radioactivity was detected in the remainder of the
carcass including the liver and the kidneys.
Rats
Wistar rats (3 male animals; age not stated) were given a single oral dose (50 mg/kg bw) of 3H-
labelled talc (synthetically produced magnesium hydrogen metasilicate) by gavage (Phillips et al.,
1978). Urine and faeces samples were collected at 24 h intervals for 4 days and then on day 10
following administration. Animals were sacriﬁced and the liver, kidneys and the gastrointestinal tract
were removed. Radioactivity in urine, faeces and tissues were determined. Three additional male rats
were administered a daily oral dose of 3H-labelled talc (50 mg/kg bw per day) for 6 consecutive days.
The animals were sacriﬁced 10 days after the ﬁnal dosing and radioactivity determined in urine, faeces
and tissues. Following the single dose of 3H-labelled talc, approximately 75% and 95.8% of radioactivity
was found in the faeces within the ﬁrst 24 h, and 96 h, respectively. By 24 h after administration, only
0.08% of the dose remained in the gastrointestinal tract. A total of less than 2% of the administered
radioactivity was found in the urine. There was no radioactivity in the liver or kidneys 10 days following
administration of 3H-labelled talc. Furthermore, after 10 days, no radioactivity was detected in the
faeces or the livers of animals which were administered 6 consecutive daily doses of 3H-labelled talc.
Less than 0.02% of the total administered radioactivity was found in the kidneys.
Hamsters
The oral absorption of talc (baby powder, no more details on composition) was investigated using
Syrian golden hamsters (6 females; 10 weeks old) (Wehner et al., 1977). Irradiated (neutron-
activated) talc was suspended in physiological saline solution and 1 mL of the suspension was
administered to the animals by gavage. Control animals (4 females; 10 weeks old) received 1 mL of
saline solution. The animals were housed in metabolism cages for 24 h, then, the animals were killed
and the skinned carcass, gastrointestinal tract, lungs, liver, kidneys and collected urine and faeces
were analysed for radioactive isotopes using gamma-ray spectrometry. Overall, approximately 74.5%
of the administered dose was found in the faeces, 23.5% in the gastrointestinal tract and 1.9% in the
carcass, but not in the lungs, liver or kidneys. The authors estimated that no more than a further 1%
would be absorbed from the gut. The Panel agreed with the authors.
Guinea pigs
Dunkin/Hartley guinea pigs (3 female animals) were given a single oral dose (25 mg/kg bw) of 3H-
labelled talc (synthetically produced magnesium hydrogen metasilicate) by gavage (Phillips et al.,
1978). Urine and faeces were collected at 24 h intervals for 4 days. After 10 days, the animals were
sacriﬁced, and the liver, kidney and gastrointestinal tract removed for determination of radioactivity.
Approximately 32% of the radioactivity was detected in the faeces within the ﬁrst 24 h, and 94.6%
was present within 96 h. By day 10, less than 0.03% of the administered dose was detected in the
gastrointestinal tract. Very little (< 0.2%) of the total radioactivity was present in the urine up to 4
days following administration.
Human studies
Calcium silicate
No studies were available.
Magnesium silicate
No studies were available.
Magnesium trisilicate
Twenty-four-hour excretion of urine was collected at several-day intervals and the ‘silica’ content
(expressed as silicon dioxide, method of determination not stated) was quantitatively determined for
each 24-h period in ﬁve healthy young males (no further details provided) (Page et al., 1941). The
mean average daily excretion of ﬁve normal subjects on a regular diet was 16.2 mg SiO2. Synthetic
hydrated magnesium trisilicate was then given to each subject in the form of 0.5 g compressed
products suspended in water. Five grams were given daily in ﬁve spaced doses of 1 g each for four
consecutive days. On the second day, urine was collected and contained 172, 178 and 162 mg SiO2 on
the second, third and fourth days, respectively. Two days after magnesium trisilicate had been
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stopped, the excretion had fallen to 24.5 mg and reported by the authors to be within the normal
excretion range of these subjects.
The 24-h urinary excretion of silicon was determined by atomic absorption spectroscopy in a
healthy adult male and healthy adult female on a normal diet, in four consecutive urine collections
(Dobbie and Smith, 1982). Then, a single dose of magnesium trisilicate (2 g for the male; 2.5 g for the
female) was ingested by the participants at the beginning of the second 24-h collection period. These
studies were repeated with higher doses (5 and 10 g for the male; 5, 7.5 and 10 g for the female).
There was a signiﬁcant increase above basal levels in urinary silicon in the 24-h urinary in both
subjects at all doses after ingestion. Maximum excretion occurred in the ﬁrst 24 h after ingestion and
amounts greater than in the predose collections (mean of 0.31 mmoles (8.7 mg) in females) continued
to be excreted on the subsequent 2 days in some instances. The amounts excreted after a 5 g dose
were greater than following the 2 g and 2.5 g doses. Little further increase in urinary silicon resulted
from raising the dose to 7.5 or 10 g.
Urinary excretion of silicon was studied in healthy adults (no further information given) on either a low
silicon diet, normal diet or after ingestion of 5 g magnesium trisilicate (Dobbie and Smith, 1986). The
excretion of silicon in urine was dependent on the amount of silicon in the diets, being lower in individuals
on the low silicon diet and higher in individuals that received continuous antacid therapy. Urinary samples
from individuals on a normal diet were collected for 2 months. These samples showed that there are
minor daily ﬂuctuations in silicon urinary excretion. In individuals who received 5 g magnesium trisilicate
antacid, urinary excretion of silicon increased 3- to 38-fold in the ﬁrst 24 h after magnesium trisilicate
ingestion and remained elevated for a further 2 days. In two other healthy subjects (no further details),
frequent, simultaneous measurements of urinary and serum silicon concentrations were made for 24 h
following ingestion of 5 g magnesium trisilicate. Peak urinary and serum concentrations of silicon were
reached after 1–2 h (10.68 mmol/L and 2- to 3-fold above the baseline of approximately 30 lmol/L,
respectively). This study also demonstrated the importance of the kidney in the excretion of silicon by
comparing the excretion of silicon in healthy adults and in patients with chronic renal failure. It was
shown that in healthy individuals, serum silicon concentrations are maintained within a narrow range, but
that hypersilicaemia can develop in individuals with kidney disease.
Silicon absorption from magnesium trisilicate was studied in healthy volunteers with normal kidney
function and not taking silicon supplements or any medication (Sripanyakorn et al., 2009). Blood
samples were collected at 30 min intervals for the ﬁrst 2 h, then at 1-h intervals for a further 4 h.
Urine was collected in two 3-h collections. The mean baseline fasting serum silicon concentration for all
participants reported in this study was 113.9 lg/mL. There was a statistically signiﬁcant increase in
urinary silicon over the 6-h collection period following ingestion of magnesium trisilicate (p < 0.001),
with urinary silicon greatest in the second 3-h collection period. The proportion of the dose excreted in
urine was 3.7% for magnesium trisilicate. According to the authors, slow absorption of magnesium
trisilicate is related to its buffering activity. As the initial disaggregation of magnesium trisilicate may
require acid digestion, silicate dissolution would be slow and relatively short-lived; therefore, the
percentage absorption from antacids would be of small magnitude.
Overall, the Panel considered that the silicate anion from calcium silicate or magnesium trisilicate is
absorbed to a limited extent in rats with evidence that absorption is saturable. No data were available
for magnesium silicate.
Based on a 2-year study with calcium silicate incorporated in the diet in rats, the Panel considered
that at high doses (up to 5,000 mg/kg bw per day), there is evidence of silicon accumulation in the
liver and kidney.
The Panel considered that data in humans with magnesium trisilicate indicated that silicate anion is
absorbed to a limited extent (less than 5%) similarly to rodents, becomes systemically available and
silicon is excreted in the urine. No human data were available for calcium silicate or magnesium silicate.
The Panel considered that a read-across approach from magnesium trisilicate was appropriate and
considered that silicate anion from both calcium silicate or magnesium silicate would be absorbed and
excreted similarly in man.
The Panel noted that studies with synthetically produced talc in mice, rat and guinea pigs as well as
talc (baby powder) in hamsters indicated that less than 2% of talc was systemically available with low
levels found in the liver.
The Panel considered that calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium
trisilicate (E 553a(ii)) and talc (E 553b) dissociate to a limited extent in the gastrointestinal tract into
silicates and their corresponding cations. The resulting amounts of calcium and magnesium ions
released were considered too low to disturb normal physiological processes and therefore, the
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consequence of ingesting them from the use of the food additives E 552, E 553a and E 553b are not
discussed further in this opinion.
3.5.2. Acute toxicity
Calcium silicate
A series of experiments with male Sprague–Dawley rats were reported by Litton Bionetics Inc (1974a).
Ten male rats (average weight 250 g) were administered a single oral dose of calcium silicate
(Silene EF) (5,000 mg/kg bw) suspended in 0.85% saline by gavage. All of the animals died within 24
h. At necropsy, bloody stomach mucosa with distension, pleural ﬂuid present and lung congestion was
reported (Litton Bionetics Inc, 1974a).
Rats (5 males/group, average weight 250 g) were administered a single oral dose of calcium
silicate (Silene EF) (0, 100, 500, 1,000, 2,000, 3,000 or 4,000 mg/kg bw) suspended in 0.85% saline
by gavage. All animals were necropsied following a 10-day observation period. There were no deaths
up to 1000 mg/kg bw, and 1/5, 2/5, and 3/5 deaths in the 2,000, 3,000, and 4,000 mg/kg bw groups,
respectively. The necropsy ﬁndings in the animals that died receiving 2,000, 3,000 and 4,000 mg
calcium silicate/kg bw during the 10-day observation period were bloody stomach mucosa with
distension, pleural ﬂuid present and lung congestion. The LD50 was determined by the authors to be
3,400 mg/kg bw (Litton Bionetics Inc, 1974a).
In another experiment, 10 male rats (average weight 385 g) were administered a single oral dose
of 5,000 mg/kg bw calcium silicate (Silene EF) (as a 24.1% w/v suspension in saline) and were
observed for the following 7 days (Litton Bionetics Inc, 1974a). There were no deaths, no signs of
toxicity or abnormal necropsy ﬁndings. The LD50 was concluded by the authors to be greater than
5,000 mg/kg bw.
Magnesium silicate
In the Hill Top Biolaps (1989 (Documentation provide to EFSA n 19)) study (GLP-compliant), ﬁve
females and ﬁve males Harlan Sprague–Dawley rats received 5,000 mg/kg bw of magnesium trisilicate
in distilled water. No deaths occurred during the observation period.
In the Tox Monitor Laboratories, Inc (2000 (Documentation provide to EFSA n 28)) study (GLP-
compliant), ﬁve females and ﬁve males Harlan Sprague–Dawley rats received by gavage 5,000 mg/kg
bw of magnesium trisilicate in distilled water. No deaths occurred during the observation period.
From these two studies, the authors concluded that the LD50 for magnesium silicates in rats was
higher than 5,000 mg/kg bw.
Magnesium trisilicate
No studies were available.
Talc
Ten male Sprague–Dawley CD rats (average weight 250 g) were administered a single oral dose of
talc (5,000 mg/kg bw) suspended in 0.85% saline by gavage. All of the animals died within 24 h. At
necropsy, impacted stomach, patchy liver and bloody ﬂuid in the stomach and intestine were reported
(Litton Bionetics Inc, 1974b).
Sprague–Dawley CD rats (5 males/group, average weight 250 g) were administered a single oral
dose of talc (0, 50, 100, 500, 1,000, 2,000 or 3,000 mg/kg bw) suspended in saline by gavage. All
animals were necropsied following a 10-day observation period. There were no deaths or adverse
necropsy ﬁndings in the groups that received 50 or 100 mg/kg bw. In the 500, 1,000, 2,000 and
3,000 mg/kg bw groups, the numbers of deaths were 1/5, 3/5, 4/5 and 5/5, respectively. The necropsy
ﬁndings in the animals that died receiving 500, 1,000, 2,000 or 3,000 mg talc/kg bw during the 10-day
observation period were impacted stomach, patchy liver and bloody ﬂuid in the stomach and intestine.
The LD50 was determined by the authors to be 920 mg/kg bw (Litton Bionetics Inc, 1974b).
In a second experiment, 10 male Sprague–Dawley CD rats (average weight 219 g) were
administered a single oral dose of 5,000 mg/kg bw talc (as a 18.3% w/v suspension in saline) and
were observed for the following 7 days. There were no deaths, no signs of toxicity or abnormal
necropsy ﬁndings. The LD50 was concluded by the authors to be greater than 5,000 mg/kg bw (no
further details were available on this study) (Litton Bionetics Inc, 1974b).
Overall, based on the available studies the Panel considered that calcium silicate, magnesium
silicate and talc have a low acute oral toxicity. No studies were available for magnesium trisilicate;
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however, the Panel considered that a read-across approach was appropriate and that it would also
have a low acute toxicity.
3.5.3. Short-term and subchronic toxicity
Calcium silicate
Calcium silicate (Silene EF) was added at levels of 0%, 1%, 5%, 10% and 20% (equivalent to 0,
1,200, 6,000, 12,000 or 24,000 mg/kg bw per day) to the feed and given to male and female
Carworth Farms strain rats (n = 15 per group) for 4 weeks (Hazelton Laboratory, 1956 (Documentation
provide to EFSA n 18)). After 2 weeks, the rats receiving 10% and 20% in the diet exhibited very poor
weight gain, unthrifty appearance and severe signs of respiratory infections and were killed. In order
to avoid the dusty and alkalinity nature of the test material, calcium silicate was mixed with gelatine
and the doses received by the animals of the previous 1% and 5% groups were elevated at 10% and
20% for the remaining 2 weeks. At termination of the study, no gross pathology could be attributed to
the ingestion of the test material; only hard faecal pellets were found in the large intestine of the
animals having received doses of 5% for 2 weeks and then 20% for the 2 following weeks.
Magnesium silicate
No studies were available.
Magnesium trisilicate
Rats
Charles River rats (15 animals/sex per group; age not speciﬁed) were fed semi-synthetic diets
containing magnesium trisilicate (1,800 mg/kg bw per day) (Newberne and Wilson, 1970). Control
animals received untreated diet. All animals were examined daily and weighed weekly. Urinary speciﬁc
gravity, and urinary protein and glucose concentrations were measured before dosing began, and then at
weekly intervals. Total and differential white blood cell counts, packed cell volume, prothrombin time,
serum concentrations of haemoglobin and urea nitrogen were all measured before dosing began, and
then at weekly intervals. At the end of the 4-week dosing period, all animals were sacriﬁced and
necropsied. Organ weights were determined and a complete set of tissues preserved for histopathological
examination (tissues and organs examined not speciﬁed). The only clinical ﬁndings were occasional
polydipsia, polyuria and soft stools seen intermittently in a few animals, clinical parameters were within
normal limits. No adverse histopathological ﬁndings were reported.
Guinea pigs
Guinea pigs (6 males, strain not speciﬁed; age and weight not stated) were given a suspension of
magnesium trisilicate in their drinking water for 4 months (5 days/week) (Dobbie and Smith, 1982). The
dose of magnesium trisilicate in water was estimated by the study author to be 50–100 mg magnesium
trisilicate/kg bw per day. Normal tap water was given to the control group throughout, and on 2 days/
week for the test group. According to the authors, tap water in their study had a silicon concentration of
0.2 mg/L, and a soluble silicon concentration of 10 lmol/L. After 4 months, all animals were killed and a
necropsy examination of the kidneys conducted (no other organs were examined). Kidney sections were
examined microscopically for a birefringent material using crossed prisms. There were no kidney lesions
in control animals. All six animals treated with magnesium trisilicate developed renal lesions with a similar
distribution pattern and severity, which predominantly affected the distal nephron. The affected
segments showed dilatation or cystic change, and some tubules were ‘plugged’ with ‘proteinaceous
material’. In the regions of the affected tubules, the interstitium was expanded by chronic inﬂammatory
inﬁltrate and an excess of collagen ﬁbres. There were no abnormal ﬁndings involving the glomeruli. The
Panel also noted that the magnesium trisilicate used in this study was prepared by the authors by
crushing and milling in order to obtain particles ranging from 0.5 to 40 lm.
Dogs
Pure bred Beagle dogs (6–9 animals/sex per group; approximately 6 months old) were fed diets
containing magnesium trisilicate (1,800 mg/kg bw per day) for 4 weeks. The protocol was the same as
the one used for the rat study described above (Newberne and Wilson, 1970). A few of the dogs had
polydipsia and polyuria, and most of the treated animals had occasional soft faeces discoloured by
unabsorbed test substance. All animals developed gross cortical lesions of the kidney. Histopathological
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examination revealed hypertrophy of tubular epithelium (with or without degenerative changes),
inﬂammatory cell inﬁltration into the interstitium and dilatation of some and collapse of other tubules.
These ﬁndings were observed with varying severity within localised areas of the kidney. Occasional
crystalline deposits characteristic of mineralisation were observed in degenerated tubular epithelium.
The glomeruli were not affected. The author of the study concluded that the observed renal effects
were due to irritation followed by degenerative and regenerative changes, accompanied by
inﬂammatory cell inﬁltration into the interstitium. However, impairment of renal function was not
detected by any of the clinical tests in urine and serum. The authors suggested that a study of longer
duration could have revealed that kind of impairment of renal function.
Talc
Rats
Talc was tested in a 5-day toxicity study in Sprague–Dawley rats (10 males; 10–12 weeks old,
average weight 367 g)) (Litton Bionetics Inc, 1974b). The animals were administered by gavage with
5,000 mg/kg bw per day for 5 days and observed for 14 days. The authors reported animals showing
slightly rough fur, decreased activity and light-coloured faeces; no adverse pathological ﬁndings were
reported.
Singh et al. treated 6 male/female Wister rats (not further speciﬁed) with 0.14 mg talc/kg bw per
day (talc not characterised) for 16 weeks (Singh et al., 2014) or 20 weeks (Singh et al., 2016) and
observed a signiﬁcant increase in blood glucose and triglyceride levels accompanied by a decrease in
blood insulin levels, which according to the authors suggested that oral exposure to talc may cause
diabetes and insulin resistance (Singh et al., 2016).
Two groups (5 animals/group) of male albino Wistar rats (100–125 g) were orally administered
talc (provided by Siddhartha Institute of Pharmacy) 10 mg/kg bw per day in saline or saline control
for 21 days (Afzal et al., 2018). Administration of talc resulted in a signiﬁcant increase in body weight
(140  23.17 g) compared to saline control (103  5.56 g). At termination, blood levels of glucose in
talc-treated animals were 194.0  9.48 mg/dL compared to 79.4  5.49 mg/dL in saline controls.
Blood creatinine and urea were statistically signiﬁcantly increased in talc-treated animals 1.3- and
2.1-fold, respectively. Serum cholesterol and triglycerides were also statistically signiﬁcantly increased
in talc-treated animals 2.4- and 9.7-fold, respectively, whereas serum HDL was statistically signiﬁcantly
decreased (0.73-fold) in talc-treated animals. Talc administration also resulted in a slight increase in
serum ALT and AST of 1.4- and 1.3-fold, respectively. However, although statistically signiﬁcant, the
Panel considered these changes in liver serum enzyme not of toxicological signiﬁcance.
The Panel noted the very low levels of talc used in the studies of Singh et al. (2014, 2016) and
Afzal et al. (2018) as compared to 5,000 mg/kg bw per day in the study of Litton Bionetics Inc
(1974b). Additionally, the Panel noted that the talc used for the studies of Singh et al. (2014 and)
Singh et al. (2016) and Afzal et al. (2018) was not characterised and, according to Singh et al. (2016),
‘may contain a variety of elements such as nickel and iron’ (not further speciﬁed). The
Panel considered that it was unclear how talc (E 553b), which is known to be hardly absorbed, could
induce such a signiﬁcant increase in body weight and diabetes in rats, and particularly at such low
doses. Therefore, the Panel considered that the results of these studies could not be used for the
hazard characterisation of talc (E 553b).
Overall, no adverse effects were observed in limited short-term and subchronic toxicity studies in rats.
The kidney effects observed in dogs when treated with magnesium trisilicate were most probably related
to the large amount of test compound administered as a bolus dose. The effects on the kidney reported
in guinea pigs treated with magnesium trisilicate could be due to higher concentrations in the primary
urine as a consequence of lower glomerular ﬁltration-rates in guinea pigs (2.29 mL plasma/min per kg;
Neiberger, 1992) as compared to rats (4.63 mL plasma/min per kg; Pestel et al., 2007).
3.5.4. Genotoxicity
In vitro
Calcium silicate
In the study by Litton Bionetics Inc (1974a), calcium silicate (Silene EF) was assessed for its
mutagenicity in the reverse mutation assay using Salmonella Typhimurium strains TA1530 and G-46
and for induction of mitotic gene conversion in Saccharomyces cerevisiae (strain D3) and no
Re-evaluation of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
(E 553a(ii)) and talc (E 553b)
www.efsa.europa.eu/efsajournal 33 EFSA Journal 2018;16(8):5375
genotoxicity was observed. However, the Panel noted that the results from the bacterial gene mutation
assay are limited due to the inadequate number of S. Typhimurium tester strains used and missing
information on the use of metabolic activation and concentrations of test substance employed. In
addition, the Panel noted that the gene conversion assay with S. cerevisiae has not been validated and
it does not belong to the assays recommended for regulatory purposes (EFSA Scientiﬁc Committee,
2011). On this basis, the results were considered to be of low relevance.
In the study by (Aslam et al., 1993), the potential of calcium silicate (three different samples with a
reported purity of approximately 97% with a different percentage of calcium oxide and silica oxide) to
induce chromosomal aberrations and sister chromatid exchanges (SCE’s) was investigated in puriﬁed
Ficoll–Hypaque human lymphocytes obtained from a healthy 30-year-old male volunteer donor in the
absence of S9 metabolic activation. Peripheral blood lymphocyte cultures were incubated (in the
presence of 5-bromo-20-deoxyuridine (BrdUrd) to detect SCE’s) with each of the three samples of
calcium silicate suspension at concentrations of 0.1, 1.0, 10 or 100 lg/mL. All cultures were then
incubated in the dark at 37°C for 48 or 72 h to study chromosomal aberrations and SCE’s respectively.
Results obtained indicated that all three samples induced signiﬁcant increases of both aberrant cells
and SCE’s at the two higher concentrations of 10 and 100 lg/mL compared with the concurrent
untreated controls. For chromosomal aberrations, this result was only obtained when the gaps were
included in the statistical analyses. The authors also indicate a signiﬁcant reduction of third division
metaphase cells at the highest doseblevel (100 lg/mL). The Panel noted that ‘gaps’ should be
recorded and reported separately but not included in the total aberration frequency,z and therefore not
evaluated in the subsequent statistical analyses as indicated in the relevant OECD Guideline TG 473. In
the present case, the Panel also noted that ‘gaps’ were likely to be induced by BrdUrd, used to detect
SCE’s and normally not employed in the chromosome aberration studies. For SCE’s, despite the
reported statistically signiﬁcant increases their frequencies never doubled the baseline frequency
observed in the concurrent untreated control which is a common criteria for considering a result as
positive. In addition, biological relevance of SCEs is unclear and the test for induction of sister
chromatid exchanges does not belong to the assays recommended for regulatory purposes (EFSA
Scientiﬁc Committee, 2011). Overall, the Panel considered that the study had some shortcomings,
however, it does not indicate any genotoxic potential of calcium silicate.
Concentrations (1, 10 and 100 lg/mL) of calcium silicate were tested for their potential to cause
chromosomal aberrations in human embryonic lung (WI-38) cell cultures observed in anaphase in the
absence of S9 metabolic activation only (Litton Bionetics Inc, 1974a). At 24 h following addition of the
test substance, 100 cells in anaphase from each culture were analysed for chromosomal aberrations
and no cytogenetic effects were observed. However, the Panel noted that this assay has not been
validated and does not belong to the assays recommended for regulatory purposes (EFSA Scientiﬁc
Committee, 2011).
Magnesium silicate
In the study by Prival et al. (1991), magnesium silicate21 was assessed for its mutagenicity in the
reverse mutation assay using the Salmonella Typhimurium strains TA1535, TA1537, TA1538, TA98,
TA100 and the E. coli strain WP2 according to the method of Ames by the plate incorporation method
both in the absence and presence of S9 metabolic activation and no induction of mutations was
observed. The Panel noted that this study was essentially performed in compliance with the OECD
guideline no. 471.
Magnesium trisilicate
No studies were available.
Talc
In the study by Litton Bionetics Inc (1974b) talc was assessed for its mutagenicity in the reverse
mutation assay using S. Typhimurium strains TA1530 and G-46 and for induction of mitotic gene
conversion in S. cerevisiae (strain D3) and no genotoxicity was observed. However, the Panel noted
that the results from the bacteria gene mutation assay are limited due to the inadequate number of
S. Typhimurium tester strains used and missing information on the use of metabolic activation and
concentrations of test substance employed. In addition, the Panel noted that the gene conversion
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assay with S. cerevisiae has not been validated and does not belong to the assays recommended for
regulatory purposes (EFSA Scientiﬁc Committee, 2011).
Concentrations (2, 20 and 200 lg/mL) of talc were tested for their potential to cause chromosomal
aberrations in human embryonic lung (WI-38) cell cultures observed in anaphase in the absence of S9
metabolic activation only (Litton Bionetics Inc, 1974b). At 24 h following addition of the test substance,
100 cells in anaphase from each culture were analysed for chromosomal aberrations and no cytogenetic
effects were observed. However, the Panel noted that this assay has not been validated and does not
belong to the assays recommended for regulatory purposes (EFSA Scientiﬁc Committee, 2011).
In the study by Endo-Capron et al. (1993), the genotoxicity of talc was evaluated in rat pleural
mesothelial cells using the unscheduled DNA synthesis (UDS) and SCE’s assays. For the induction of
UDS, three different samples of talc with particle size in the respirable range were incubated with the
cells for 24 h. Each talc sample was tested at a concentration of 50, 100 and 250 lg/mL in the
medium and each concentration was replicated six times. Anatase was tested as the negative control
and did not increase UDS. Crocidolite and chrysotile were used as the positive controls and both
showed enhancement of UDS. None of the talc samples increased UDS. For the induction of SCE’s,
samples of talc were treated at 2, 5, 10 or 15 lg/mL and incubated for 48 h at 37°C in the dark. No
induction of SCE’s was observed with any talc sample at any concentration tested. Similarly, negative
control particles, attapulgite and anatase did not induce SCE’s. Positive controls mitomycin C and
potassium chromate induced statistically signiﬁcant increases of SCE’s while crocidolite did not show
consistent positive result. On this basis, the authors concluded that equivocal results for the positive
control crocidolite weakened the strength of the study. The Panel agreed with this conclusion and
noted that the biological relevance of SCE is unclear and that the assay does not belong to those
recommended for regulatory purposes (EFSA Scientiﬁc Committee, 2011).
In vivo
Calcium silicate
In a host-mediated assay, groups of 10 male IBR mice were administered calcium silicate (Silene
EF) by gavage at 15, 150 and 1,500 mg/kg either once (acutely) or on ﬁve consecutive days 24 h
apart (Litton Bionetics Inc, 1974a). Negative and positive control animal groups were also included.
The highest dose level of calcium silicate (1,500 mg/kg) corresponded to the calculated LD5. The
indicator organisms used in this study were: (i) two histidine auxotrophs (his G-46, TA-1530) of
S. Typhimurium for induction of reverse mutation and (ii) a diploid strain (D-3) of S. cerevisiae for the
induction of mitotic gene conversion. Both for the acute and subacute studies, within 30 min from the
last administration, all animals received 2 mL of the indicator organism, intraperitoneally, each mL
containing 3.0 9 108 cells for Salmonella and 5.0 9 108 cells for Saccharomyces. Three hours after
the injection of the indicator organism, the mice were sacriﬁced and the host cells were aseptically
washed out of the peritoneum of each animal and plated under standard conditions. A second
experiment was additionally performed under the same experimental conditions with only one dose
level of calcium silicate but at 5,000 mg/kg. Results obtained in both experiments indicated that
calcium silicate did not show genotoxic activity in any of the indicator organisms and dose levels
employed. The Panel noted that the host mediated assay does not belong to those recommended for
regulatory purposes (EFSA Scientiﬁc Committee, 2011).
In an in vivo cytogenetic assay, the induction by calcium silicate (Silene EF) of chromosomal
aberrations in bone marrow cells of rats was investigated (Litton Bionetics Inc, 1974a). Groups of ﬁve
male albino rats were administered with test substance by gavage acutely at 15, 150 and 1,500 mg/kg
bw or subacutely on ﬁve consecutive days, 24 h apart, at the same dose levels employed for the acute
treatment. Negative and positive control animal groups were also included. For the acute treatment,
sampling of bone marrow cells was performed at 6, 24 and 48 h from the last administration, while in
the subacute study, sampling was only performed at 6 h from the last administration. A second
experiment was additionally performed under the same experimental conditions with only one dose-
level of calcium silicate at 5,000 mg/kg. Results obtained indicated that calcium silicate induced no
increases in the incidence of chromosomal aberrations in the bone marrow cells following both acute
and subacute administration, at any of the dose level employed. The Panel noted that this study,
essentially complies with the OECD Guideline 475 requirements, although it was performed before this
Guideline was established.
In a dominant lethal assay, calcium silicate (Silene EF) was administered by gavage to groups of
ten male albino rats acutely at 15, 150 and 1,500 mg/kg bw or subacutely on ﬁve consecutive days,
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24 h apart, at the same dose levels employed for the acute treatment (Litton Bionetics Inc, 1974a).
Negative and positive control animal groups were also included. Following treatment, the males were
sequentially mated to two females per week for 8 weeks (7 weeks in the subacute study) and housed
separately until sacriﬁce. A second experiment was additionally performed under the same
experimental conditions with only one dose level of calcium silicate but at 5,000 mg/kg. Fertility index,
total implants (live fetuses plus early and late fetal deaths), total dead (early and late fetal deaths),
dead implants per total implants and preimplantation loss (calculated as the difference between the
total corpora lutea and total implant counts) were evaluated and according to the authors, the results
did not raise concern with respect to genotoxicity. The Panel agreed with this conclusion.
Magnesium silicate
No studies were available.
Magnesium trisilicate
No studies were available.
Talc
In a host-mediated assay, groups of 10 male IBR mice were administered talc by gavage at 30, 300
and 3,000 mg/kg either once (acutely) or on ﬁve consecutive days 24 h apart (Litton Bionetics Inc,
1974b). Negative and positive control animal groups were also included. The highest dose level of talc
(3,000 mg/kg) corresponded to the calculated LD5. The indicator organisms used in this study were:
(i) two histidine auxotrophs (his G-46, TA-1530) of S. Typhimurium for induction of reverse mutation
and (ii) a diploid strain (D-3) of S. cerevisiae for the induction of mitotic gene conversion. Both for the
acute and subacute studies, within 30 min from the last administration, all animals received 2 mL of
the indicator organism, intraperitoneally, each mL containing 3.0 9 108 cells for Salmonella and
5.0 9 108 cells for Saccharomyces. Three hours after the injection of the indicator organism, the mice
were sacriﬁced and the host cells were aseptically washed out of the peritoneum of each animal and
plated under standard conditions. A second experiment was additionally performed under the same
experimental conditions with only one dose-level of talc but at 5,000 mg/kg. Results obtained in both
experiments indicated that talc did not show genotoxic activity in any of the indicator organisms and
dose-levels employed. The Panel noted that the host mediated assay does not belong to those
recommended for regulatory purposes (EFSA Scientiﬁc Committee, 2011).
In an in vivo cytogenetic assay, the induction by talc of chromosomal aberrations in bone marrow
cells of rats was investigated (Litton Bionetics Inc, 1974b). Groups of ﬁve male albino rats were
administered with talc by gavage acutely at 30, 300 and 3,000 mg/kg bw or subacutely on ﬁve
consecutive days, 24 h apart, at the same dose levels employed for the acute treatment. Negative and
positive control animal groups were also included. For the acute treatment, sampling of bone marrow
cells was performed at 6, 24 and 48 h from the last administration, while in the subacute study
sampling was only performed at 6 h from the last administration. A second experiment was
additionally performed under the same experimental conditions with only one dose level of talc but at
5,000 mg/kg. Results obtained indicated that talc induced no increases in the incidence of
chromosomal aberrations in the bone marrow cells following both acute and subacute administration,
at any of the dose level employed. The Panel noted that this study, essentially complies with the OECD
Guideline 475 requirements, although it was performed before this Guideline was established.
In a dominant lethal assay, talc was administered by gavage to groups of 10 male albino rats
acutely at 15, 150 and 1,500 mg/kg bw or subacutely on ﬁve consecutive days, 24 h apart, at the
same dose levels employed for the acute treatment (Litton Bionetics Inc, 1974b). Negative and
positive control animal groups were also included. Following treatment, the males were sequentially
mated to two females per week for 8 weeks (7 weeks in the subacute study) and housed separately
until sacriﬁce. A second experiment was additionally performed under the same experimental
conditions with only one dose level of talc but at 5,000 mg/kg. Fertility index, total implants (live
fetuses plus early and late fetal deaths), total dead (early and late fetal deaths), dead implants per
total implants and preimplantation loss (calculated as the difference between the total corpora lutea
and total implant counts) were evaluated. Results obtained indicated that talc induced signiﬁcant
decreases in corpora lutea at week 5 in the acute treatment and signiﬁcant increases in the average
resorption and in dead implants at week 6. However, these effects revealed no dose–response or time-
trend pattern. No effects were observed at 5,000 mg/kg for the acute treatment. The author
concluded that talc does not induce dominant lethal mutations under the reported experimental
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condition. The Panel agreed with this conclusion and further noted that the number of animals
employed for this study was low.
Overall, the Panel considered that the available data did not raise concern with respect to
genotoxicity of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a
(ii)) and talc (E 553b).
3.5.5. Chronic toxicity and carcinogenicity
Carworth rats (15 male and 15 female weanlings/group) were fed a diet containing 0, 1%, 5%,
7.5% or 10% (equivalent to 0, 500, 2,500, 3,750 and 5,000 mg/kg bw per day, respectively) calcium
silicate (Silene EF) as a gelatine mix (Hazelton Laboratory, 1956 [Documentation provided to EFSA No
xx). The groups fed 7.5% and 10% were initially treated with diet containing 5% calcium silicate for the
ﬁrst 4 weeks followed by diet containing 7.5% calcium silicate to acclimatise the animals to the diet.
The highest dose group was fed a diet containing 10% calcium silicate from 11 weeks. Control animals
were fed diet containing gelatine only. Blood counts were made on 10 male and 10 female rats selected
at random at the beginning of the study. Three male and three female rats from each group were
randomly selected at weeks 13, 52 and 104 and blood counts performed. During week 104, ﬁve male
and ﬁve female rats from each group were randomly selected and urinary pH determined. Pooled faeces
were collected prior to termination for the determination of silicon dioxide content. The study was
terminated at 104 weeks, and liver, kidney and spleen wet weights determined. Silicon dioxide levels
were determined in the liver, spleen, kidney, skeletal muscle and cardiac muscle tissues (organs from
three animals of each sex were pooled; six animals in total/sex were used in these determinations).
Silicon dioxide levels were also determined in the testes (three animals were pooled; six animals in total
were used in this determination). The thyroid, lung, heart, liver, stomach, large and small intestines,
pancreas, spleen, kidney, adrenal, urinary bladder, gonads, bone marrow and skeletal muscle were
collected from six male and six female rats/group, ﬁxed and examined histopathologically. The
appearance and behaviour of the rats were comparable in all groups. The faeces of rats in the 7.5%
and 10% calcium silicate were hard and lighter in colour than the control groups and the majority of
rats in these groups exhibited signs of mild constipation. Average silicon dioxide contents in organs
showed a dose-dependent increase in the liver and kidney, with the highest levels found in the kidney.
During the ﬁrst year, both male and female rats in the 7.5% and 10% calcium silicate groups exhibited
signiﬁcant growth retardation. However, from 78 weeks, this retardation was only apparent in the 10%
calcium silicate group. No signiﬁcant difference in blood haemoglobin, total red and white cell counts or
differential count throughout the study. The average urinary pH values of all experimental groups were
not signiﬁcantly increased over control values for both sexes. There was no effect on mortality. No gross
pathology or histopathological ﬁndings that could be attributed to calcium silicate were observed in rats
of the 1% and 5% calcium silicate groups. Dilated hepatic portal veins and bile ducts, and cholangitis
were noted in 3 males and one female of the 7.5% and in two males of the 10% groups. The authors
reported that at necropsy of animals that died during the study, ‘the primary cause of death was an
overwhelming respiratory infection’. The Panel noted that although the authors reported that ‘silicon
dioxide was determined in faeces and in a series of organs’, the methodology used for this
determination measured in fact total silicon as silicates; in addition, phosphorus strongly interferes in
this method and has to be removed before measurement of silicates. The Panel considered that this
study was not conducted according to the current standard. Particularly, only 15 animals per sex per
group were used, no reliable clinical chemistry and haematological evaluation was conducted and
animals had respiratory infection. The Panel noted that there was no indication on carcinogenicity;
however, due to further limitations (histopathological examination was performed on only six animals
per sex per group and on a limited number of organs and tissues) it was not possible to conclude on
the chronic toxicity of calcium silicate.
There was no data for oral chronic toxicity/carcinogenicity of talc.
3.5.6. Reproductive and developmental toxicity
Reproductive toxicity studies
No studies were available.
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Developmental studies
Calcium silicate
Mice
Pregnant CD-1 mice (20–23 animals/group) were treated with calcium silicate (Silene EF) by gavage
once daily from gestation day (GD) 6 to 15 with doses of 16, 74, 350 and 1,600 mg/kg bw per day in
water (1 mL/kg bw) (FDRL, 1972 (Documentation provide to EFSA n 15)). The control group was
dosed with 1 mL corn oil/kg bw. At necropsy on GD 17, the surviving dams appeared to be completely
normal and the number of implantations, and live fetuses were comparable to the control group.
Doses up to 1,600 mg calcium silicate/kg bw per day had no noticeable effects on implantation nor on
maternal and fetal survival. The numbers of live or dead fetuses, resorptions and implantations, as well
as the fetal weights did not differ among the groups. The sex distribution of fetuses was not affected
by the treatment. The number of abnormalities seen in either soft tissues or skeletons at fetal
pathological examination of the calcium silicate-treated groups, did not differ from the number in
vehicle-treated dams of the control group.
Rats
Pregnant Wistar rats (20–22 animals/group) were treated with calcium silicate (Silene EF) by
gavage once daily from GD 6 to 15 with doses of 16, 74, 350 and 1,600 mg/kg bw per day in water
(1 mL/kg bw) (FDRL, 1972 (Documentation provide to EFSA n 15)). The control group was dosed with
1 mL corn oil/kg bw. At necropsy on GD 20, animals that had received doses up to 1,600 mg calcium
silicate/kg bw per day appeared to be completely normal and had no noticeable effects on
implantation nor on maternal and fetal survival. The numbers of live or dead fetuses, resorptions,
implantations and fetal weights did not differ among the groups. The sex distribution of fetuses was
not affected by the treatment. The number of abnormalities seen in either soft tissues or skeletons at
fetal pathological examination of the calcium silicate-treated groups did not differ from the number in
vehicle-treated dams of the control group.
Hamsters
Pregnant Golden hamsters (19–22 animals/group) were treated with calcium silicate (Silene EF) by
gavage once daily from GD 6 to 10 of gestation with doses of 0, 16, 74, 350 or 1,600 mg/kg bw per
day in water (1 mL/kg bw) (FDRL, 1972 (Documentation provide to EFSA n 15)). The control group
was dosed with 1 mL corn oil/kg bw. At necropsy on GD 14, animals that had received doses up to
1,600 mg calcium silicate/kg bw per day appeared to be completely normal and showed no noticeable
effects on implantation nor on maternal and fetal survival. The numbers of live or dead fetuses,
resorptions, implantations or fetal weights did not differ amongst the groups. The sex distribution of
fetuses was not affected by the treatment. The number of abnormalities seen in either soft tissues or
skeletons at fetal pathological examination of the calcium silicate-treated groups, did not differ from
the number in vehicle-treated dams of the control group.
Rabbits
Artiﬁcially inseminated Dutch-belted rabbits (15–33 animals/group) were treated with calcium
silicate (Silene EF) by gavage once daily from GD 6 to 18 with doses of 0, 16, 74, 350 or 1,600 mg/kg
bw per day in water (8, 11, 12, 10 or 11 pregnant surviving females/group, respectively) (FDRL,
1973a). The mortality in this study was 3, 6, 3, 2 and 9 does in the respective groups. In addition,
many animals per group were non-pregnant (5, 9, 11, 14 and 15 does in the respective groups). At
necropsy on GD 20, animals that had received doses up to 1,600 mg calcium silicate/kg bw per day
appeared to be completely normal and had no noticeable effects on implantation nor on maternal and
fetal survival. The numbers of live or dead fetuses, resorptions, implantations and fetal weights did not
differ amongst the groups. The sex distribution of fetuses was not affected by the treatment. The
number of abnormalities seen in either soft tissues or skeletons at fetal pathological examination of the
calcium silicate-treated groups, did not differ from the number in vehicle-treated dams of the control
group. The Panel noted that due to the high mortality and the low pregnancy rate, this study cannot
be used for hazard assessment.
Magnesium silicate
No studies were available.
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Magnesium trisilicate
No studies were available.
Talc
Mice
Pregnant CD-1 mice (21–22 animals/group) were treated by gavage once daily from GD 6 to 15
with doses of 0, 16, 74, 350 and 1,600 mg talc/kg bw per day suspended in corn oil (dose volume not
described) (FDRL, 1973b). At necropsy on GD 17, the surviving dams appeared to be completely
normal and the number of implantations, and live fetuses were comparable to the control group.
Doses up to 1,600 mg talc/kg bw per day had no noticeable effects on implantation nor on maternal
and fetal survival. The numbers of live or dead fetuses, resorptions, implantations and also fetal
weights did not differ among the groups. The sex distribution of fetuses was not affected by the
treatment. The number of abnormalities seen in either soft tissues or skeletons at fetal pathological
examination of the treated groups did not differ from the number in vehicle-treated dams of the
control group.
Rats
Pregnant Wistar rats (20–23 animals/group) were treated by gavage once daily from GD 6 to 15
with doses of 0, 16, 74, 350 and 1,600 mg talc/kg bw per day suspended in corn oil (dose volume not
described) (FDRL, 1973b). At necropsy on GD 20, animals that had received doses up to 1,600 mg
talc/kg bw per day appeared to be completely normal and had no noticeable effects on implantation
nor on maternal and fetal survival. The numbers of live or dead fetuses, resorptions, implantations and
fetal weights did not differ amongst the groups. The sex distribution of fetuses was not affected by the
treatment. The number of abnormalities seen in either soft tissues or skeletons at fetal pathological
examination of the talc-treated groups did not differ from the number in vehicle-treated dams of the
control group.
Hamsters
Pregnant Golden hamsters (19–21 animals/group) were treated by gavage once daily from GD 6 to
10 with doses of 0, 12, 56, 260 or 1,200 mg talc/kg bw per day suspended in corn oil (dose volume
not described) (FDRL, 1973b). Does of the high-dose group lost weight from GD 6 to 8. At necropsy
on GD 14, animals that had received doses up to 1,200 mg talc/kg bw per day appeared to be
completely normal and showed no noticeable effects on implantation nor on maternal and fetal
survival. The numbers of live or dead fetuses, resorptions, implantations or fetal weights did not differ
amongst the groups. The sex distribution of fetuses was not affected by the treatment. The number of
abnormalities seen in either soft tissues at fetal pathological examination of the talc-treated
groups, did not differ from the number in vehicle-treated dams of the control group. Fetuses of the
1,200 mg/kg bw per day group showed skeletal retardation, which is most likely due to decreased
body weights of the does.
Rabbits
Artiﬁcially inseminated Dutch-belted rabbits (14–29 animals/group) were treated by gavage once
daily from GD 6 to 18 with doses of 0, 9, 42, 195 or 900 mg talc/kg bw per day suspended in corn oil
(7, 11, 10, 10 or 11 pregnant surviving females/group, respectively) (FDRL, 1973c). Dose volume in
the control and high-dose groups was 4 mL corn oil/kg bw per day and in the other groups 1 mL corn
oil/kg bw per day. The mortality in this study was 2, 5, 4 and 7 including one aborted, two does in the
respective groups. In addition, many animals per group were non-pregnant (6, 10, 11, 15 and 2 in the
respective groups). At necropsy on GD 20, animals that had received doses up to 900 mg talc/kg bw
per day appeared to be completely normal and had no noticeable effects on implantation nor on
maternal and fetal survival. The numbers of live or dead fetuses, resorptions, implantations and fetal
weights did not differ among the groups. The sex distribution of fetuses was not affected by the
treatment. The number of abnormalities seen in either soft tissues or skeletons at fetal pathological
examination of the talc-treated groups, did not differ from the number in vehicle-treated dams of the
control group. The Panel noted that due to the high mortality and the low pregnancy rate, this study
cannot be used for hazard assessment.
Overall, no reproductive study was available. Prenatal developmental toxicity studies with calcium
silicate by gavage during organogenesis in mice, rats and hamsters (FDRL, 1972 (Documentation
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provide to EFSA n 15)) and with talc (FDRL, 1973b) in mice and rats up to 1,600 mg/kg bw per day
(the highest dose tested), showed no dose-related developmental effects.
3.5.7. Other studies
Human studies
A case report involving a patient with a history of renal colic who had taken the equivalent of 2 g
magnesium trisilicate (as an antacid) with every meal for many years was available (Joekes et al.,
1973). The 68-year-old male was ﬁrst examined in 1971, at which point he had a history of two
episodes of presumed renal colic. The patient had passed several bladder stones through the 1960s.
The authors of the study commented that the patient was not certain how long he had been ingesting
magnesium trisilicate, but it could have been from 1940, when renal colic was ﬁrst diagnosed. Analysis
of stones passed in urine in 1971 revealed that they predominantly consisted of opaline silica. The
author of this study did not consider the intake of magnesium trisilicate to be excessive, and that if the
stones were due to magnesium trisilicate then more silica stones should have be reported. However,
the authors also reported that stone analysis in hospitals was limited, so the composition of the stones
might not be accurate.
Treatment with silicate antacid drugs such as magnesium trisilicate resulting in urinary silicate
calculi (Lee et al., 1993) are seldom found in humans (0.1–0.2% of all urinary stones). They are
mostly found in adults but they have also been described in rare cases in children (Tasdemir et al.,
2017), where they were associated with consumption of milk thickener containing 5.5% silicates in one
case of a 6-month-old boy (Ulinski et al., 2004), or milk powder dissolved in silicate-rich mineral water
(estimated daily intake of about 200 mg silicate) in a 10 month old boy (Nishizono et al., 2004).
The Panel noted that cases of renal calculi were rarely reported in the EudraVigilance database
(online) considering the high number of exposed humans to magnesium trisilicate used as antacid. The
Panel applied the WHO algorithm for assessing the association between adverse events and drug
intake (Edwards and Biriell, 1994) and found that the association between silicate antacid use and
renal calculi was ‘possible’ but not ‘deﬁnite’, which does not exclude that the occurrence of renal calculi
and intake of silicates would be a chance ﬁnding.
3.6. Discussion
In previous evaluations, calcium silicate (E 552) and magnesium silicate (E 553a) have been
combined with silicon dioxide (E 551). However, the ANS Panel provided a separate scientiﬁc opinion
re-evaluating the safety of silicon dioxide (E 551) when used as a food additive, therefore not covering
the silicates (E 552–553). The present opinion describes the re-evaluation of calcium silicate (E 552),
magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b) when used as food
additives.
According to Commission Regulation (EU) No 231/2012, the food additive calcium silicate (E 552) is
deﬁned as ‘a hydrous or anhydrous silicate with varying proportions of CaO and SiO2’; magnesium
silicate (E 553a(i)) is deﬁned as ‘a synthetic compound of which the molar ratio of magnesium oxide to
silicon dioxide is approximately 2:5’ Although calcium silicate (E 552) and magnesium silicate (E 553(i))
may be described in terms of theoretical oxides, the Panel considered that they are not mixtures of
silicon dioxide and calcium or magnesium oxides and, therefore, their deﬁnitions in the EU
speciﬁcations should be revised accordingly. No deﬁnition for magnesium trisilicate (E 553a(ii)) is
included in the EU speciﬁcations.
The water solubility of calcium silicate has been reported to be about 260 mg/L, though this
requires a method which extends the measurement time for several days (CEFIC, 2017a
(Documentation provided to EFSA n. 4)). The Panel considered this solubility indicates that calcium
silicate and magnesium silicate are ‘very slightly soluble’ at equilibrium. According to Commission
Regulation (EU) No 231/2012, magnesium trisilicate is insoluble in water and ethanol; however the
Panel considered that a similar behaviour to calcium silicate and magnesium silicate would be expected
at equilibrium for magnesium trisilicate. This assumption is also supported by the literature (Rashid
et al., 2011). According to Commission Regulation (EU) No 231/2012 and information from industry
(EUROTALC, 2018; Documentation provided to EFSA n. X), talc is insoluble in water.
Following an EFSA request, LD and TEM data for calcium silicate were provided. The Panel noted
that these methods measure different particle characteristics, which are reﬂected in the different
numerical size-values obtained. Taking into account the analysis by TEM provided by industry, calcium
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silicate falls under the deﬁnition of nanomaterial according to the Commission Recommendation
2011/696/EU. However, the Panel considered that the dispersion method (sonication) of the sample
before its analysis by TEM is not representative of the common use of calcium silicate as a food
additive. Following an EFSA request, no TEM data were provided for magnesium silicate (E 553a(i))
and magnesium trisilicate (E 553a(ii)). SEM data for talc indicated a range of particle size distribution
of 20–40 lm (EUROTALC, 2018; Documentation provided to EFSA n. X).
The Panel noted that crystalline silica (alpha-quartz) may be present as an associated mineral,
according to the EU speciﬁcations for talc (E 553b). Crystalline silica is a class 1 carcinogen by
inhalation (IARC, 1997) and no maximum limit for quartz has been established in the EU speciﬁcations
for talc (E 553b). The Panel also noted that no maximum limit has been set for ﬂuoride, while
phlogopite (contains ﬂuorine) is another possible associated mineral in talc (E 553b) according to the
EU speciﬁcations. Therefore, the Panel considered that maximum limit for crystalline silica and ﬂuoride
should be included in the EU speciﬁcations for talc (E 553b).
The Panel considered that silicates may be determined in food via measuring the total silicon;
however, under these conditions, it cannot be differentiated whether the measured silicon content
originates from the added silicates or from other sources of silicon. The Panel also noted that no
speciﬁc analysis for the presence of silicates or their particles in food have been reported in the
literature.
General methods for the analysis of silicates are available but they relate mainly to the analysis of
aqueous samples. Talc may be quantiﬁed through burning a sample of food/beverage in a furnace for
1 h at 500°C to remove organic components, followed by detection by X-ray diffraction.
The Panel considered that calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium
trisilicate (E 553a(ii)) and talc (E 553b) are stable in food when used as food additives.
The Panel considered that in some biological studies, authors reported analysis of ‘silica’ or of
‘silicon dioxide’ content while analytical methods available at the time were only capable of measuring
total silicon either measured as such or as silicate anion after transformation. Therefore, it was not
possible for the Panel to determine whether it was silica, silicates or silicon that was measured.
The Panel considered that silicate anion from both calcium silicate or magnesium trisilicate was
absorbed to a limited extent in rats. No data were available for magnesium silicate.
Based on a 2-year study with calcium silicate in rats, the Panel considered that at high doses (up to
5,000 mg/kg bw per day), there was evidence of silicon accumulation in the liver and kidney. The
Panel considered that limited data in humans indicated that the silicate anion from magnesium
trisilicate is absorbed to a limited extent, then excreted in the urine (as determined from urinary silicon
measurements). No human data were available for calcium silicate or magnesium silicate; however, the
Panel considered that a read-across approach was appropriate and considered that silicate anion from
both calcium silicate and magnesium silicate would behave similarly.
The Panel noted that studies with synthetically produced talc in mice, rat and guinea pigs as well as
talc (baby powder) in hamsters indicated that less than 2% talc was systemically available, with low
levels seldom found in the liver.
The Panel considered that calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium
trisilicate (E 553a(ii)) and talc (E 553b) dissociate to a limited extent in the gastrointestinal tract into
silicates and their corresponding cations. The resulting low amounts of calcium and magnesium ions
were considered not to disturb normal physiological processes and, therefore, the properties of the
corresponding cations are not discussed further in this opinion.
The Panel considered that calcium silicate, magnesium silicate and talc have a low acute oral
toxicity. No studies were available for magnesium trisilicate.
No adverse effects were observed in limited short-term and in subchronic toxicity studies in rats.
The kidney effects observed in dogs were most probably related to the large amount of test
compound consumed as a bolus dose by the animals. The effects on the kidney reported in guinea
pigs could be due to higher concentrations of silicate in the primary urine as a consequence of lower
glomerular ﬁltration rates in guinea pigs (2.29 mL plasma/min per kg) as compared to rats (4.63 mL
plasma/min pe kg). The Panel noted that in humans the glomerular ﬁltration rate (3.56 mL plasma/min
per kg) is higher than in guinea pigs and, furthermore, kidney effects have not been found in humans
in the EudraVigilance database despite the wide and long-term use of high doses of magnesium
trisilicate (up to 4 g/person per day) as an antacid over decades.
The Panel considered that the available data did not raise concern with respect to genotoxicity of calcium
silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b).
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In a 2-year study in rats, not performed according to current standards, calcium silicate (Silene EF)
had no effect on mortality at a dose up to 5,000 mg/kg bw per day. No gross pathology or
histopathological ﬁndings that could be attributed to calcium silicate were observed in the 500 and
2,500 mg/kg bw per day groups. However, in the absence of clinical chemistry data, given the
respiratory infection of animals and only 15 animals/sex per group, the Panel considered that this
study was too limited to conclude on the chronic toxicity of calcium silicate. However, the Panel noted
that no carcinogenic effects were reported in this study.
There was no data for oral chronic toxicity/carcinogenicity of talc.
No reproductive toxicity studies were available. Prenatal developmental toxicity studies with calcium
silicate (Silene EF) by gavage during organogenesis in mice, rats and hamsters (FDRL, 1972) and with
talc (FDRL, 1973b) in mice and rats up to 1,600 mg/kg bw per day (the highest dose tested), showed
no dose-related developmental effects.
Treatment with silicate antacid drugs such as magnesium trisilicate resulting in urinary silicate calculi
(Lee et al., 1993) are seldom found in humans (0.1–0.2% of all urinary stones). They are mostly found
in adults but they have also been described in rare cases in children (Tasdemir et al., 2017), where they
were associated with consumption of milk thickener containing 5.5% silicates in one case of a 6-month-
old boy (Ulinski et al., 2004), or milk powder dissolved in silicate-rich mineral water (water containing
172 mg silicate/L; estimated daily intake of about 200 mg silicate) in a 10 month old boy (Nishizono
et al., 2004). The Panel noted that cases of renal calculi were rarely reported considering the high
number of exposed humans to magnesium trisilicate used as an antacid. The Panel applied the WHO
algorithm for assessing the association between adverse events and drug intake and found that
association between silicate antacid use and renal calculi was ‘possible’ but not ‘deﬁnite’, which does not
exclude that the occurrence of renal calculi and intake of silicates would be a chance ﬁnding.
In the available data on subacute toxicity, genotoxicity and developmental toxicity studies, no adverse
effects were reported for silicates and talc. From the only chronic toxicity study (with calcium silicate)
available, there was no indication for carcinogenicity. However, due to the limitations of this study, it was
not possible to draw a reliable conclusion on the chronic toxicity and carcinogenicity of calcium silicate.
Furthermore, no subchronic and reproductive toxicity studies with silicates or talc were available.
The Panel noted that the biological and toxicological studies performed with Silene EF were
conducted with a hydrated calcium silicate described as having an average particle size of 30 nm
(Columbia-Southern Chemical Corporation, 1953 (Documentation provided to EFSA n. 8)).
The Panel noted that the SCF established a group ADI ‘not speciﬁed’ for sodium silicate, silicon
dioxide, calcium silicate, magnesium silicate and potassium silicate (SCF, 1991) presumably on the
basis that they share a common moiety. The Panel noted that more recent evidence suggested that
this assumption might not be valid. Therefore, the Panel considered that on the evidence currently
available, there is no mechanistic rationale for a group ADI for silicates and silicon dioxide. Therefore
the Panel considered this group ADI obsolete.
Due to the limitations in the available toxicological database for individual silicates, the Panel was
unable to derive ADIs for calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate
(E 553a(ii)) and talc (E 553b).
Silicates (E 552-553) are authorised in 28 food categories, including FC 0, according to Annex II to
Regulation (EC) No 1333/2008. Their use in FC 0 means that they are ‘permitted in all categories of
foods excluding foods for infants and young children, except where speciﬁcally provided for’. Silicates
(E 552–553) are also authorised according to Annex III to Regulation (EC) No 1333/2008 (Parts 1, 2
and 5 A) in food-improving agents and nutrients, except nutrients intended for foods for infants and
young children. As such, silicates (E 552–553) can be found in many foods via carry-over. The industry
provided use levels for silicates (E 552–553) for their use according to Annex II. No analytical data on
the concentration of these food additives in foods were made available by the Member States.
Dietary exposure to silicates (E 552–553) from their use as food additives according to Annex II
was calculated for different exposure scenarios based on the provided use levels (Section 3.4). The
Panel noted that 287 (98%) out of the 292 reported use levels applied in the exposure scenarios
related to the use of talc (E 553b) (Appendix A). This reported use was in line with the information
from the Mintel GNPD, showing that 89% of the foods labelled with silicates (E 552–553) were labelled
to contain talc (E 553b). Therefore, the Panel noted that the calculated exposure reﬂects chieﬂy the
exposure to talc (E 553b).
Additionally, 266 (91%) out of the 292 reported use levels were related to the use of silicates
(E 552–553) in food supplements, again mainly talc (E 553b). The Panel noted that the main food
category labelled with silicates (E 552–553) in the Mintel GNPD was also food supplements
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(Appendix B). Therefore, the Panel considered the food supplements consumers only scenario as the
most appropriate scenario for risk characterisation of silicates (E 552–553). Dietary exposure to
silicates (E 552–553) via this exposure scenario was up to 31 mg/kg bw per day at the mean level in
children and up to 46 mg/kg bw per day at the high (P95) level in the elderly.
The exposure assessment was hampered by several uncertainties (Table 8). Overall, it was
considered that the exposure was most likely overestimated due to the use levels used and
assumptions made in the exposure assessment. For a more detailed discussion on the uncertainties,
see Section 3.4.5. Furthermore, the Panel noted that no foods belonging to an important contributing
food category in all population groups, i.e. ripened cheese, were labelled to contain silicates
(E 552-553) according to the Mintel GNPD.
The Panel noted that the exposure estimates were based on reported use levels of silicates (E 552–
553). If current practice changes, these reﬁned estimates may no longer be representative and should
be updated.
Considering the possible high levels of nickel and aluminium in chlorite, an associated mineral in
talc (E 553b), the Panel estimated the potential worst case exposure to these elements of concern
from the use of silicates (E 552–553). Based on the mean intake for the population group with highest
exposure (children) in the food supplement scenario, and the reported level of chlorite (9% w/w),
exposure to nickel from the use of silicates (E 552–553) as food additives could be around 300 times
its tolerable daily intake (TDI) of 2.8 lg/kg bw (EFSA CONTAM Panel, 2015). Exposure to aluminium
could be around ﬁve times its tolerable weekly intake (TWI) of 1 mg/kg bw (EFSA, 2008). Therefore,
the Panel considered that maximum limits for aluminium and nickel should be included in the EU
speciﬁcations for talc (E 553b).
4. Conclusions
The Panel noted that:
• the absorption of silicates and talc was very low;
• there was no indication for genotoxicity or developmental toxicity for calcium and magnesium
silicate and talc;
• no conﬁrmed cases of kidney effects have been found in the EudraVigilance database despite
the wide and long-term use of high doses of magnesium trisilicate up to 4 g/person/day over
decades.
However, the Panel considered that accumulation of silicon from calcium silicate in kidney and liver
was reported in rats and reliable data on subchronic and chronic toxicity, carcinogenicity, and that
reproductive toxicity of silicates and talc were lacking. Therefore, the Panel concluded that the safety
of calcium silicate (E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc
(E 553b) when used as food additives cannot be assessed.
The Panel also concluded that due to the uncertainties regarding a common moiety, the current
group ADI for sodium silicate, silicon dioxide, calcium silicate, magnesium silicate and potassium
silicate could not be mechanistically justiﬁed. The Panel concluded that on the available toxicological
database for silicates it was not possible to establish ADIs for calcium silicate (E 552), magnesium
silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b).
Based on the food supplement scenario considered as most representative for risk characterisation,
exposure to silicates (E 552–553) for all population groups was below the maximum daily dose of
magnesium trisilicate used as antacid (4 g/person per day).
The Panel noted that there were a number of approaches which could decrease the uncertainties in
the current toxicological database. These approaches include but are not limited to toxicological
studies as recommended for Tier 1 approach as described in the EFSA Guidance for the submission of
food additives (EFSA ANS Panel, 2012) and conducted with adequately characterised material. Since
the available data showed that nano particles are present in calcium silicate (E 552), the studies
should be conducted with a material that contains a fraction of nano particles typical for silicates used
as food additives.
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5. Recommendations
The Panel recommended that:
• the European Commission considers the revision of the EU speciﬁcations for calcium silicate
(E 552), magnesium silicate (E 553a(i)), magnesium trisilicate (E 553a(ii)) and talc (E 553b) in
order to include better deﬁnitions, assays in line with the deﬁnitions, and characterisation of
particle size distributions (using appropriate statistical descriptors (e.g. range, median,
quartiles) as well as the percentages (in number and by mass) of particles in the nanoscale
(with at least one dimension < 100 nm). With regard to the characterisation of the particle
size distribution, the analytical methodologies applied should comply with those recommended
in the EFSA Guidance on risk assessment of the application of nanoscience and
nanotechnologies in the food and feed chain (EFSA Scientiﬁc Committee, 2018)).
• in ﬁrst instance, toxicological studies as recommended for a Tier 1 approach as described in
the EFSA Guidance for the submission of food additives (EFSA ANS Panel, 2012) should be
conducted with adequately characterised material(s) in order to decrease the uncertainties in
the current toxicological database.
• more data on the actual usage and use levels of silicates (E 552, E 553a(i)) and E 553a(ii))
should be provided because most of the data submitted were for talc (E 553b).
• the European Commission considers lowering the current limits for toxic elements (arsenic,
lead and mercury) in the EU speciﬁcations for calcium silicate (E 552), magnesium silicate
(E 553a(i)), magnesium trisilicate, (E 553a(ii)) and talc (E 553b) in order to ensure that the
food additives will not be a signiﬁcant source of exposure to these toxic elements in food.
• the European Commission considers inclusion of maximum limits for aluminium, nickel, ﬂuoride
and crystalline silica (alpha-quartz) in the EU speciﬁcations for talc (E 553b).
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Glossary and Abbreviations
AESGP Association of the European Self-Medication Industry
ADI acceptable daily intake
ANS EFSA Panel on Food Additives and Nutrient Sources added to Food
ASASP Association of Synthetic Amorphous Silica Producers
bw body weight
CAS Chemical Abstracts Service
EINECS European Inventory of Existing Commercial Chemical Substances
ESA European Snacks Association/SNACMA
EVM Expert Group on Vitamins and Minerals
FC food category
FCS food categorisation system
FDA Food and Drug Administration
FDE Food Drink Europe
FDRL Food and Drug Research Laboratories
FSE Food Supplements Europe
GD gestation day
GLP good laboratory practice
GNPD Global New Products Database
IARC International Agency for Research on Cancer
ICGA International Chewing Gum Association
ISO International Organization for Standardization
JECFA Joint FAO/WHO Expert Committee on Food Additives
LD laser diffraction
LD5 lethal dose, 5%, i.e. dose that causes death among 5% of treated animals
LD50 lethal dose, median
MPL maximum permission limit
MS mass spectrometry
OECD Organisation for Economic Co-operation and Development
QS quantum satis
REACH Registration, Evaluation, Authorisation and Restriction of Chemicals
SSA speciﬁc surface area
SCF Scientiﬁc Committee on Food
SEM scanning electron microscopy
SNE Specialised Nutrition Europe
TEM transmission electron microscopy
TemaNord is a publishing series for results of the often research-based work that working groups or
projects under Nordic Council of Ministers have put in motion
TDI tolerable daily intake
TWI tolerable weekly intake
UDS unscheduled DNA synthesis
WHO World Health Organization
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